EP0730660A1 - Proteines chimeres contenant des variantes de la protease nexine-1 - Google Patents
Proteines chimeres contenant des variantes de la protease nexine-1Info
- Publication number
- EP0730660A1 EP0730660A1 EP94931834A EP94931834A EP0730660A1 EP 0730660 A1 EP0730660 A1 EP 0730660A1 EP 94931834 A EP94931834 A EP 94931834A EP 94931834 A EP94931834 A EP 94931834A EP 0730660 A1 EP0730660 A1 EP 0730660A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- protein
- amino acid
- protease
- variant
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102100033299 Glia-derived nexin Human genes 0.000 title claims description 152
- 101710183811 Glia-derived nexin Proteins 0.000 title claims description 152
- 108020001507 fusion proteins Proteins 0.000 title abstract description 36
- 102000037865 fusion proteins Human genes 0.000 title abstract description 36
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 358
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 343
- 238000000034 method Methods 0.000 claims abstract description 91
- 235000018102 proteins Nutrition 0.000 claims description 339
- 229920001223 polyethylene glycol Polymers 0.000 claims description 146
- 239000002202 Polyethylene glycol Substances 0.000 claims description 97
- 239000004365 Protease Substances 0.000 claims description 84
- 102000035195 Peptidases Human genes 0.000 claims description 83
- 108091005804 Peptidases Proteins 0.000 claims description 83
- 235000001014 amino acid Nutrition 0.000 claims description 68
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 63
- 150000001413 amino acids Chemical class 0.000 claims description 61
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 56
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 56
- 125000000539 amino acid group Chemical group 0.000 claims description 53
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 50
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 50
- 235000018417 cysteine Nutrition 0.000 claims description 45
- 230000001965 increasing effect Effects 0.000 claims description 44
- 230000027455 binding Effects 0.000 claims description 41
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 40
- 229960005356 urokinase Drugs 0.000 claims description 40
- 239000000758 substrate Substances 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 35
- 108020004414 DNA Proteins 0.000 claims description 33
- 102000005962 receptors Human genes 0.000 claims description 30
- 108020003175 receptors Proteins 0.000 claims description 30
- 230000004048 modification Effects 0.000 claims description 28
- 238000012986 modification Methods 0.000 claims description 28
- 108090000190 Thrombin Proteins 0.000 claims description 27
- 229960004072 thrombin Drugs 0.000 claims description 27
- 239000003001 serine protease inhibitor Substances 0.000 claims description 25
- 239000003112 inhibitor Substances 0.000 claims description 23
- 102000001554 Hemoglobins Human genes 0.000 claims description 20
- 108010054147 Hemoglobins Proteins 0.000 claims description 20
- -1 Cl-esterase Proteins 0.000 claims description 18
- 230000008878 coupling Effects 0.000 claims description 17
- 238000010168 coupling process Methods 0.000 claims description 17
- 238000005859 coupling reaction Methods 0.000 claims description 17
- 239000012634 fragment Substances 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 125000004149 thio group Chemical group *S* 0.000 claims description 14
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 claims description 12
- 108090000617 Cathepsin G Proteins 0.000 claims description 12
- 108010074860 Factor Xa Proteins 0.000 claims description 12
- 101800004937 Protein C Proteins 0.000 claims description 12
- 102000017975 Protein C Human genes 0.000 claims description 12
- 101800001700 Saposin-D Proteins 0.000 claims description 12
- 229960000856 protein c Drugs 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 230000013595 glycosylation Effects 0.000 claims description 8
- 238000006206 glycosylation reaction Methods 0.000 claims description 8
- 108090000935 Antithrombin III Proteins 0.000 claims description 7
- 102000004411 Antithrombin III Human genes 0.000 claims description 7
- 102000004142 Trypsin Human genes 0.000 claims description 7
- 108090000631 Trypsin Proteins 0.000 claims description 7
- 229960005348 antithrombin iii Drugs 0.000 claims description 7
- 229960001322 trypsin Drugs 0.000 claims description 7
- 239000012588 trypsin Substances 0.000 claims description 7
- 102000001399 Kallikrein Human genes 0.000 claims description 6
- 108060005987 Kallikrein Proteins 0.000 claims description 6
- 101710102218 Serine protease inhibitor Proteins 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 108010014173 Factor X Proteins 0.000 claims description 5
- 229940012426 factor x Drugs 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 102100033237 Pro-epidermal growth factor Human genes 0.000 claims description 4
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 4
- 102000035118 modified proteins Human genes 0.000 claims description 4
- 108091005573 modified proteins Proteins 0.000 claims description 4
- 108090000317 Chymotrypsin Proteins 0.000 claims description 3
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 3
- 108010076282 Factor IX Proteins 0.000 claims description 3
- 108010074105 Factor Va Proteins 0.000 claims description 3
- 108010080805 Factor XIa Proteins 0.000 claims description 3
- WGNOPSQMIQERPK-UHFFFAOYSA-N Leu-Asn-Pro Natural products CC(C)CC(N)C(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)O WGNOPSQMIQERPK-UHFFFAOYSA-N 0.000 claims description 3
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 claims description 3
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 claims description 3
- 229960002376 chymotrypsin Drugs 0.000 claims description 3
- 229960004222 factor ix Drugs 0.000 claims description 3
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 2
- 229940116977 epidermal growth factor Drugs 0.000 claims description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
- 229940122055 Serine protease inhibitor Drugs 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 5
- 108010033719 glycyl-histidyl-glycine Proteins 0.000 claims 4
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 3
- NEBFIUZIGRTIFY-BJDJZHNGSA-N Ala-Met-Ser-Arg Chemical compound CSCC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NEBFIUZIGRTIFY-BJDJZHNGSA-N 0.000 claims 2
- 102000004173 Cathepsin G Human genes 0.000 claims 2
- 108010048049 Factor IXa Proteins 0.000 claims 2
- 108090000481 Heparin Cofactor II Proteins 0.000 claims 2
- 102100030500 Heparin cofactor 2 Human genes 0.000 claims 2
- 101000836058 Mus musculus Serine protease inhibitor A3C Proteins 0.000 claims 2
- 102000010752 Plasminogen Inactivators Human genes 0.000 claims 2
- 108010077971 Plasminogen Inactivators Proteins 0.000 claims 2
- 101000836071 Rattus norvegicus Serine protease inhibitor A3K Proteins 0.000 claims 2
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 claims 2
- 239000002797 plasminogen activator inhibitor Substances 0.000 claims 2
- 102000055157 Complement C1 Inhibitor Human genes 0.000 claims 1
- 108700040183 Complement C1 Inhibitor Proteins 0.000 claims 1
- 108050002150 EGF-like domains Proteins 0.000 claims 1
- 102000012545 EGF-like domains Human genes 0.000 claims 1
- 108010061932 Factor VIIIa Proteins 0.000 claims 1
- 229940009550 c1 esterase inhibitor Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 description 97
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 63
- 229960002897 heparin Drugs 0.000 description 63
- 229920000669 heparin Polymers 0.000 description 63
- 229940024606 amino acid Drugs 0.000 description 61
- 235000019419 proteases Nutrition 0.000 description 57
- 239000000203 mixture Substances 0.000 description 48
- 238000006243 chemical reaction Methods 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 40
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 36
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 32
- 108090000394 Erythropoietin Proteins 0.000 description 30
- 102000003951 Erythropoietin Human genes 0.000 description 30
- 102000012479 Serine Proteases Human genes 0.000 description 30
- 108010022999 Serine Proteases Proteins 0.000 description 30
- 238000002741 site-directed mutagenesis Methods 0.000 description 29
- 238000006467 substitution reaction Methods 0.000 description 28
- 238000011282 treatment Methods 0.000 description 28
- 229940012957 plasmin Drugs 0.000 description 27
- 238000009472 formulation Methods 0.000 description 26
- 239000003153 chemical reaction reagent Substances 0.000 description 25
- 229940105423 erythropoietin Drugs 0.000 description 25
- 230000006320 pegylation Effects 0.000 description 24
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 24
- 108010088842 Fibrinolysin Proteins 0.000 description 23
- 102000002265 Human Growth Hormone Human genes 0.000 description 23
- 108010000521 Human Growth Hormone Proteins 0.000 description 23
- 230000002401 inhibitory effect Effects 0.000 description 23
- 239000000854 Human Growth Hormone Substances 0.000 description 22
- 102000008847 Serpin Human genes 0.000 description 22
- 108050000761 Serpin Proteins 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 20
- 206010061218 Inflammation Diseases 0.000 description 19
- 239000000872 buffer Substances 0.000 description 19
- 230000004054 inflammatory process Effects 0.000 description 19
- 230000035772 mutation Effects 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 108091006006 PEGylated Proteins Proteins 0.000 description 17
- 230000008901 benefit Effects 0.000 description 15
- 108091026890 Coding region Proteins 0.000 description 14
- 108091034117 Oligonucleotide Proteins 0.000 description 13
- 239000007983 Tris buffer Substances 0.000 description 13
- 230000007935 neutral effect Effects 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 239000004475 Arginine Substances 0.000 description 11
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 10
- 108010024976 Asparaginase Proteins 0.000 description 10
- 102100025975 Cathepsin G Human genes 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 230000004071 biological effect Effects 0.000 description 10
- 238000005119 centrifugation Methods 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 9
- 230000002797 proteolythic effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 8
- 229920002684 Sepharose Polymers 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 210000002744 extracellular matrix Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000701447 unidentified baculovirus Species 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 7
- 102000008300 Mutant Proteins Human genes 0.000 description 7
- 108010021466 Mutant Proteins Proteins 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 229960003272 asparaginase Drugs 0.000 description 7
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000003602 elastase inhibitor Substances 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000010911 Enzyme Precursors Human genes 0.000 description 6
- 108010062466 Enzyme Precursors Proteins 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 102000016611 Proteoglycans Human genes 0.000 description 6
- 108010067787 Proteoglycans Proteins 0.000 description 6
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 6
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 6
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 5
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 5
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 108010079944 Interferon-alpha2b Proteins 0.000 description 5
- 101710180313 Protease 3 Proteins 0.000 description 5
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 239000012736 aqueous medium Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 210000003000 inclusion body Anatomy 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000004474 valine Substances 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 4
- 102000055025 Adenosine deaminases Human genes 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 102100040018 Interferon alpha-2 Human genes 0.000 description 4
- 102100034876 Kallikrein-9 Human genes 0.000 description 4
- 101710176226 Kallikrein-9 Proteins 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 206010040070 Septic Shock Diseases 0.000 description 4
- 108010023197 Streptokinase Proteins 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 108010092464 Urate Oxidase Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
- 229960005202 streptokinase Drugs 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 3
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 3
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 3
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 3
- 102000004452 Arginase Human genes 0.000 description 3
- 108700024123 Arginases Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 3
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 239000007990 PIPES buffer Substances 0.000 description 3
- 108010007544 Protease Nexins Proteins 0.000 description 3
- 102000007324 Protease Nexins Human genes 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 3
- 230000020176 deacylation Effects 0.000 description 3
- 238000005947 deacylation reaction Methods 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000003953 foreskin Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000009145 protein modification Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- ZCWMSMLAGCXPPA-FHQLIMNDSA-N (2s)-1-[(2s)-2-[[(2s)-2-aminopropanoyl]amino]propanoyl]-n-[(2s)-1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 ZCWMSMLAGCXPPA-FHQLIMNDSA-N 0.000 description 2
- 101710129138 ATP synthase subunit 9, mitochondrial Proteins 0.000 description 2
- 101710168506 ATP synthase subunit C, plastid Proteins 0.000 description 2
- 101710114069 ATP synthase subunit c Proteins 0.000 description 2
- 101710197943 ATP synthase subunit c, chloroplastic Proteins 0.000 description 2
- 101710187091 ATP synthase subunit c, sodium ion specific Proteins 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 108010027612 Batroxobin Proteins 0.000 description 2
- 102100035882 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229940122858 Elastase inhibitor Drugs 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 206010014824 Endotoxic shock Diseases 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 2
- 101001010513 Homo sapiens Leukocyte elastase inhibitor Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108700023158 Phenylalanine ammonia-lyases Proteins 0.000 description 2
- 102000001938 Plasminogen Activators Human genes 0.000 description 2
- 108010001014 Plasminogen Activators Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108090000787 Subtilisin Proteins 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 2
- 108010010711 alpha 1-antitrypsin-leukocyte elastase complex Proteins 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229920005603 alternating copolymer Polymers 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 229960002210 batroxobin Drugs 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 229940105657 catalase Drugs 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000009585 enzyme analysis Methods 0.000 description 2
- 238000002270 exclusion chromatography Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 102000019758 lipid binding proteins Human genes 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229940127126 plasminogen activator Drugs 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000012289 standard assay Methods 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- YDMBNDUHUNWWRP-VJBWXMMDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]piperidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C1=CC=CC=C1 YDMBNDUHUNWWRP-VJBWXMMDSA-N 0.000 description 1
- FCNSOUPAGQGYCT-USJZOSNVSA-N (2s)-1-[(2s)-2-[[(2s)-2-aminopropanoyl]amino]propanoyl]-n-[(2s)-3-methyl-1-(4-nitroanilino)-1-oxobutan-2-yl]pyrrolidine-2-carboxamide Chemical compound N([C@@H](C(C)C)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](C)N FCNSOUPAGQGYCT-USJZOSNVSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- WPVINHLVHHPBMK-ULQDDVLXSA-N (2s)-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]-1-[(2s)-5-oxopyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound C([C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)CCN1C(=O)[C@@H]1CCC(=O)N1 WPVINHLVHHPBMK-ULQDDVLXSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- PZEUTLIKVUEDLB-UHFFFAOYSA-N 2-[[[2-[[6-amino-2-[[2-[[6-amino-2-[[2-[[2-[[2-[[2-[[2-[2-[[1-[2-[[2-[[2-[[2-[[2-[[2-[[6-amino-2-[[2-[[2-[2-[[2-[[2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]acetyl]amino]propanoylamino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]propanoylamino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-(carbamoylamino)propanoyl]-(3-amino-3-oxopropyl)carbamoyl]amino]pentanediamide Chemical compound CCC(C)C(NC(=O)CN)C(=O)NCC(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(CO)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(C(C)CC)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CNC(N)=O)C(=O)N(CCC(N)=O)C(=O)NC(CCC(N)=O)C(N)=O PZEUTLIKVUEDLB-UHFFFAOYSA-N 0.000 description 1
- VLWQPMPFPUXBLV-UHFFFAOYSA-N 4-(2,5-dioxopyrrol-1-yl)butanoic acid;1-hydroxypyrrolidine-2,5-dione Chemical compound ON1C(=O)CCC1=O.OC(=O)CCCN1C(=O)C=CC1=O VLWQPMPFPUXBLV-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- DAEFQZCYZKRTLR-ZLUOBGJFSA-N Ala-Cys-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(O)=O DAEFQZCYZKRTLR-ZLUOBGJFSA-N 0.000 description 1
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 1
- 101001094887 Ambrosia artemisiifolia Pectate lyase 1 Proteins 0.000 description 1
- 101001123576 Ambrosia artemisiifolia Pectate lyase 2 Proteins 0.000 description 1
- 101001123572 Ambrosia artemisiifolia Pectate lyase 3 Proteins 0.000 description 1
- 101000573177 Ambrosia artemisiifolia Pectate lyase 5 Proteins 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- LRPZJPMQGKGHSG-XGEHTFHBSA-N Arg-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N)O LRPZJPMQGKGHSG-XGEHTFHBSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101000929500 Bos taurus Adenosine deaminase Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108090001069 Chymopapain Proteins 0.000 description 1
- 108090000746 Chymosin Proteins 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- XRHVZWWRFMCBAZ-UHFFFAOYSA-L Endothal-disodium Chemical compound [Na+].[Na+].C1CC2C(C([O-])=O)C(C(=O)[O-])C1O2 XRHVZWWRFMCBAZ-UHFFFAOYSA-L 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 1
- 101001122938 Homo sapiens Lysosomal protective protein Proteins 0.000 description 1
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 1
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- YSGBJIQXTIVBHZ-AJNGGQMLSA-N Ile-Lys-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O YSGBJIQXTIVBHZ-AJNGGQMLSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 206010065973 Iron Overload Diseases 0.000 description 1
- 102100024407 Jouberin Human genes 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- IRMLZWSRWSGTOP-CIUDSAMLSA-N Leu-Ser-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O IRMLZWSRWSGTOP-CIUDSAMLSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- YRWCPXOFBKTCFY-NUTKFTJISA-N Lys-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCCCN)N YRWCPXOFBKTCFY-NUTKFTJISA-N 0.000 description 1
- 102100028524 Lysosomal protective protein Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- IHITVQKJXQQGLJ-LPEHRKFASA-N Met-Asn-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N IHITVQKJXQQGLJ-LPEHRKFASA-N 0.000 description 1
- YLDSJJOGQNEQJK-AVGNSLFASA-N Met-Pro-Leu Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O YLDSJJOGQNEQJK-AVGNSLFASA-N 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- XEXSSIBQYNKFBX-KBPBESRZSA-N Phe-Gly-His Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)C1=CC=CC=C1 XEXSSIBQYNKFBX-KBPBESRZSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108090000113 Plasma Kallikrein Proteins 0.000 description 1
- 102100034869 Plasma kallikrein Human genes 0.000 description 1
- 102100024078 Plasma serine protease inhibitor Human genes 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 1
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 1
- 108010001953 Protein C Inhibitor Proteins 0.000 description 1
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 1
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 1
- 101710146873 Receptor-binding protein Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- ISWQCIVKKSOKNN-UHFFFAOYSA-L Tiron Chemical compound [Na+].[Na+].OC1=CC(S([O-])(=O)=O)=CC(S([O-])(=O)=O)=C1O ISWQCIVKKSOKNN-UHFFFAOYSA-L 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 1
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- VBTFUDNTMCHPII-FKBYEOEOSA-N Val-Trp-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O VBTFUDNTMCHPII-FKBYEOEOSA-N 0.000 description 1
- VBTFUDNTMCHPII-UHFFFAOYSA-N Val-Trp-Tyr Natural products C=1NC2=CC=CC=C2C=1CC(NC(=O)C(N)C(C)C)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 VBTFUDNTMCHPII-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 235000003484 annual ragweed Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 239000003659 bee venom Substances 0.000 description 1
- PPUGEVRMBYCGHM-GMAHTHKFSA-N benzyl n-[(2s)-1-[[2-[[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C(=O)OCC1=CC=CC=C1 PPUGEVRMBYCGHM-GMAHTHKFSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 235000006263 bur ragweed Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 229940000032 cardiovascular system drug Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229960002976 chymopapain Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 235000003488 common ragweed Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 108010075231 contrapsin Proteins 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000000495 cryogel Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002338 glycosides Chemical group 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229940066369 honey bee venom Drugs 0.000 description 1
- 102000052502 human ELANE Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108010091871 leucylmethionine Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940045258 pancrelipase Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- PXGPLTODNUVGFL-UHFFFAOYSA-N prostaglandin F2alpha Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CC=CCCCC(O)=O PXGPLTODNUVGFL-UHFFFAOYSA-N 0.000 description 1
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000003946 protein process Effects 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 235000009736 ragweed Nutrition 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 102200110980 rs28931570 Human genes 0.000 description 1
- 102220077288 rs797045007 Human genes 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 108010022069 sultilains Proteins 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229950010549 sutilains Drugs 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940005267 urate oxidase Drugs 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- This invention relates generally to the field of proteins, protein analogs, and methods of specifically altering proteins in order to change their biological activity. More particularly, the invention relates to identifying the active site of a protein, for example, Protease Nexin-1, and altering the active site by changing one or more a ino acids therein to create an analog or replacing the active site of a protein with the active site of a completely different protein to create a chi eric protein. The invention also relates to identifying cysteine residues, or amino acid residues which may be substituted by cystine without abolishing activity, and attaching polyethylene glycol to the thio group of cysteine, thereby increasing protein stability.
- a protein for example, Protease Nexin-1
- the invention also relates to identifying cysteine residues, or amino acid residues which may be substituted by cystine without abolishing activity, and attaching polyethylene glycol to the thio group of cysteine, thereby increasing protein stability.
- proteases have specific functions in the body. For example, natural physiological functions such as tissue remodeling, inflammation, coagulation, and fibrinolysis require proteolytic enzymes. Of particular importance is a mechanistic class of proteases called serine proteases. It is also known that the active site of all functional members of the serine protease family contains a characteristic catalytic triad consisting of serine (hence the name) , aspartic acid and histidine. The hydroxyl group of the catalytic site serine is involved in a nucleophilic attack on the carbonyl carbon of the peptide bond to be hydrolyzed resulting in acylation of the protease and hydrolysis of the peptide bond. This is followed rapidly by a deacylation step resulting in the release of intact protease.
- PN-1 Protease nexin-1
- Human foreskin cells Scott, R. . et al., J Biol Chem (1983) 58:1043910444. It is a 42 kd glycoprotein which is released by fibroblasts, myotubes, heart muscle cells, and vascular smooth muscle cells. Its release, along with that of plasminogen activator, is stimulated by phorbol esters and by mitogens (Eaton, D.L. et al., J Cell Biol (1983) 121:128).
- Native PN-1 is an approximately 400 amino acid protein containing about 10% carbohydrate.
- PN-1 inhibits all the known activators of urokinase proenzyme, plasmin, trypsin, thrombin, and Factor Xa (Eaton, D.L. et al., J Biol Chem (1984) 259:6241) . It also inhibits tissue plasminogen activator and urokinase. However, PN-1 does not inhibit elastase or cathepsin G.
- PN-1 acts as a substrate analogue and postulated that it might be possible to drastically alter PN-1 activity by modifying the reactive site sequence of PN-1, thus changing its protease specificity. Similar efforts with ⁇ -1-antitrypsin, for example, resulted in variants with altered and therapeutic potential (M. Courtney et al., Nature (1985) 3 -2:149-151) .
- PN-1 is different from most serpins in that it is found in tissues, contains a high affinity heparin binding site which localizes it to tissues, and has a tissue clearance receptor that is responsible for endocytosis of protease-PN-1 complexes. We were able to generate PN-1 variants as inhibitors of physiologic proteases such as elastase and thereby provide useful pharmaceutically active compounds.
- PN-1 variants including variants which inactivate elastase and cathepsin G, and have moved well beyond our prior work to provide variants and methods for designing and producing such variants which have significantly altered protease specificity and second-order association rate constants with respect to a variety of serine proteases.
- variants and methods of producing such variants which have polyethylene glycol specifically attached to one or more cysteine residues, such cysteine residues being either present in the parent molecule or introduced on the surface of the protein by site-directed mutagenesis, and methods for determining appropriate sites for the introduction of cysteine residues.
- variants and methods of producing such variants which combine the specific localization ability of a receptor-binding protein with the protease- inhibiting activity of PN-1 or variant thereof, resulting in desired biological activities with particular substrates.
- a Type I variant of the invention is produced by site-directed mutagenesis wherein a single amino acid within the active site of PN-1 is substituted with an amino acid different from the naturally-occurring amino acid at that position.
- a Type II variant of the invention is similar to a Type I variant in that the active site of PN-1 is changed. However, to produce a Type II variant, the active site of PN-1 is changed so as to match the active site of another serpin which change many require one or more amino acid substitutions, deletions or additions.
- a Type III variant of the invention is produced whereby the active site or a portion thereof of PN-1 is substituted with a sequence which corresponds to the substrate sequence for a particular protease.
- a Type IV variant is produced wherein a cysteine residue, which is either present in the native protein or introduced by site-specific mutation, is used to attach polyethylene glycol.
- a Type V variant of the invention involves producing a fusion protein wherein PN-1 is fused to the receptor binding region of another protein in order to localize PN-1 to a different receptor. Variants of Type I, II or III are referred to herein as variants.
- compositions which contain one or more variants of all or any of Type I, II, III, IV or V.
- An important object of the invention is to provide a wide range of different variants, and in particular PN-1-variants, having a particular and desired biological activity.
- Another object is to provide PN-1 variants using site-directed mutagenesis in order to change a single amino acid within the active site of PN-1.
- Another important object is to provide a PN-1- variant wherein the active site of PN-1 is specifically modified so as to match the active site of another enzyme inhibitor, preferably another serpin.
- Yet another important object of the present invention is to provide variants such as protease nexin-1 variants which include, in PN-1, the substrate sequence for a different protease, making it possible to inhibit the activity of that protease.
- Still another important object is to provide proteins which are PEGylated by attachment to a thio group, i.e. the polyethylene glycol is attached to a cysteine amino acid within a protein, which cysteine amino acid of the protein is not involved in a disulfide bond.
- Another important object is to provide a method of attaching polyethylene glycol to a protein by first subjecting the protein to site-directed mutagenesis to add a cysteine residue at a position where the protein or a structurally related protein is normally glycosylated, and thereafter attaching the polyethylene glycol to the cysteine residue.
- Another important object is to provide a method of attaching PEG to a protein by first subjecting the protein to site-directed mutagenesis to add a cysteine residue at a position on the surface of the protein, and thereafter attaching the PEG to the cysteine residue.
- Another important object is to provide dimeric or multimeric proteins cross-linked by reaction with a reagent composed of PEG having two protein-reactive moieties.
- Yet another important object is to provide fusion proteins wherein the receptor binding region of another protein is connected to PN-1 in order to localize PN-1 to a different receptor.
- Another object of the present invention is to provide a pharmaceutical composition comprising excipient carrier materials having a compound of the invention dispersed therein.
- Another object of the present invention is to provide therapeutic methods of treatment which involve administering to a patient in need thereof a pharmaceutically effective amount of a composition comprising excipients and a compound of the invention.
- a feature of the present invention is that the variants can be designed to have a specific receptor- binding domain while maintaining the natural biological activity of the protein to which the new binding domain is attached.
- An advantage of the present invention is that the variants have substantially different inhibitory effects on certain proteolytic enzymes as compared to the natural protein.
- Another object of the present invention is to provide variants useful in treating diseases associated with a specific biological activity.
- Yet another advantage of the present invention is to describe and disclose variants which are useful in treating elastase-related diseases.
- Another feature of the present invention is that certain variants have substantially altered protease specificity as compared with the natural protein.
- Another advantage of the present invention is that certain variants have substantially greater second order association rate constants with respect to particular serine proteases as compared with the second order association rate constant of natural proteins with respect to such serine proteases.
- Another advantage of the present invention is that certain variants have substantially slower second order association rate constants with respect to particular serine proteases as compared with the second order association rate constant of natural proteins with respect to such serine proteases.
- Yet another object is to provide methods of delivery such as by injection, internasal and interpulmonary delivery which methods are carried out using pharmaceutical compositions in the form of injectable formulations, spray formulations and aerosols.
- Another advantage is that biologically stabilized proteins can be produced by attaching the polyethylene glycol to a cysteine residue of the protein.
- Another advantage is to provide methodology for readily attaching polyethylene glycol molecules to proteins at a cysteine residue of the protein which are preferably located at native sites of glycosylation.
- amino acid residues for substitution with cysteine may be selected so that subsequent attachment of polyethylene glycol to the thio group of the substituted cysteine residue increases biological stability of the cysteine-PEGylated protein relative to wild type without abolishing biological activity.
- proteins which normally require glycosylation for biological stability may be produced commercially by expression in a prokaryotic host or other host which does not provide for glycosylated recombinant proteins. After expression of the protein by the prokaryotic host, biological stability of the protein can be increased by attachment of polyethylene glycol to a native or engineered cysteine residue in the protein.
- cysteine-PEGylated proteins can be produced without exposing the protein to highly toxic chemicals such as dioxane, cyanuric chloride, DMF, or other chemicals used in conventional methods for attaching polyethylene glycol to a protein.
- Figure 1 shows the nucleotide sequence of the coding region and the deduced amino acid sequence of PN-l ⁇ ;
- Figure 2 shows the nucleotide sequence of the coding region and the deduced amino acid sequence of PN-13.
- Figure 3 is a schematic drawing of a three-dimensional structure of PN-1 as determined by X- ray crystallography. The approximate position of residues of particular interest are shown according to their relative position within a given helix (h) or jS- sheet (s) .
- the helices and 3-sheets of the PN-1 protein are each assigned letters (e.g. A, B, etc.) (Engh, et al. 1990 Protein Engin . 3(6) :469-477) .
- Figure 4 is a graph which shows the activity of samples of reaction mixtures containing cysteine- PEGylated PN-1 variants (N99C;N140C) produced by the method of the invention (open squares) and the activity of samples of reaction mixtures containing a PEGylated PN-1 variant (N99C;N140C) produced by a conventional method (closed diamonds) .
- protease nexin-1 and “PN-1” are used interchangeably and refer to DNA codons and resulting amino acid sequences which make up PN-l and PN-l / S which are shown respectively in Figures l and 2.
- PN-1 is distinguishable from the two other protease nexin factors, PN-II and PN-III (Knauer, D.J. et al., J Biol Chem (1982) 257:15098-15104) . which are also thrombin inhibitors, but are less strongly binding to this protease and are of different molecular weight, three- dimensional structure and mechanism of function.
- variants proteins
- proteins proteins
- chimeric proteins are used interchangeably herein to refer to any amino acid sequence which corresponds to the amino acid sequence of a natural protein or a biologically active portion of a natural protein except that some change has been made in the structures.
- Typical changes per the present invention involve: (1) one or more amino acids within the natural sequence is replaced with one or more amino acids different from the amino acids present in the natural protein; and/or (2) one or more amino acids has been added to the natural sequence, and the addition of such amino acids changes the biological activity of the variant; and/or (3) one or more amino acids is deleted from the natural sequence; and/or (4) polyethylene glycol is bound to a thio group of a natural or artificially introduced cysteine residue of a sequence; and/or (5) two naturally occurring sequences are fused together, i.e. two sequences not normally connected are fused.
- protease nexin-1 variants and “analogs of protease nexin-1” are terms which are used synonymously herein to define a Type I variant and are thereby encompassed by the term “variant.” The terms are intended to refer generally to proteins wherein one or more of the amino acids within protease nexin-1 have been substituted with a different amino acid. More specifically, the protease nexin-1 variants of the invention include substantially the same amino acid sequence as protease nexin-1 but for the substitution of different amino acids at or near the active site.
- substitutions of different amino acids can be made at any of P j , P 2 , P 3 , P sites and/or made at the P j ' , P 2 ', or P 3 ', P 4 ' sites.
- substitutions and deletions of amino acids in the sequence of protease nexin-1 are encompassed by this invention, the substitutions at or near the active site are most important with respect to changing the specificity and/or reactivity of the variant with respect to particular proteases.
- protease nexin-1 variants of the invention are variants which have high activity relative to a substrate to which natural PN-1 has little or no activity such as variants which inhibit elastase and, more particularly, which inhibit elastase and have their ability to inhibit elastase enhanced in - li ⁇ the presence of heparin and/or heparin-like compounds.
- Other preferred protease nexin-1 variants for example, have increased ability to inhibit urokinase and/or another serine protease as compared with protease nexin-1.
- Control sequence refers to a DNA sequence or sequences which are capable, when properly ligated to a desired coding sequence, of effecting its expression in hosts compatible with such sequences. Such control sequences include at least promoters in both procaryotic and eucaryotic hosts, and preferably, transcription termination signals. Additional factors necessary or helpful in effecting expression may also be identified. As used herein, “control sequences” simply refers to whatever DNA sequence may be required to effect expression in the particular host used.
- Cells or “cell cultures” or “reco binant host cells” or “host cells” are often used interchangeably as will be clear from the context. These terms include the immediate subject cell, and, of course, the progeny thereof. It is understood that not all progeny are exactly identical to the parental cell, due to chance mutations or differences in environment. However, such altered progeny are included in these terms, so long as the progeny retain the characteristics relevant to those conferred on the originally transformed cell. In the present case, for example, such a characteristic might be the ability to produce recombinant PN-1.
- purified or pure refers to material which is free from substances which normally accompany it as found in its native state.
- pure PN-1-encoding DNA refers to DNA which is found in isolation from its native environment and free of association with DNAs encoding other proteins normally produced by cells natively producing PN-1.
- Pure PN-1 refers to PN-1 which does not contain materials normally associated with its in situ environment in human or other mammalian tissue. Of course, “pure” PN-1 may include materials in covalent association with it, such as glycoside residues or materials introduced for, for example, formulation as a therapeutic.
- pure also includes variants wherein compounds such as polyethylene glycol, Biotin or other moieties are bound to the variant in order to allow for the attachment of other compounds and/or provide for formulations useful in therapeutic treatment or diagnostic procedures.
- "Pure” simply designates a situation wherein the substance referred to is, or has been, isolated from its native environment and materials which normally accompany it.
- the DNA claimed herein as purified and free of substances normally accompanying it, but encoding PN-1 can include additional sequence at the 5' and/or 3' end of the coding sequence which might result, for example, from reverse transcription of the noncoding portions of the message when the DNA is derived from a cDNA library or might include the reverse transcript for the signal sequence as well as the mature protein encoding sequence.
- “Degenerate with”, as referred to a DNA sequence, refers to nucleotide sequences encoding the same amino acid sequence as that referenced.
- operably linked refers to a juxtaposition wherein the components are configured so as to perform a desired function such as their natural biochemical function.
- control sequences or promoters operably linked to a coding sequence are capable of effecting the expression of the coding sequence.
- Heparin "heparan sulfate” and “heparin-like compounds” are terms which are used synonymously herein. Each of the terms singly or in combination with the others is intended to encompass a large group of compounds which are generally described as sulfated polysaccharides, which includes proteoglycans and glycosammoglycans (GAG) which are alternating copolymers of a hexosamine and an aldouronic acid. These copolymers are found in sulfated forms and are synthesized as proteoglycans and are collectively referred to as mucopolysaccharides. Other compounds such as dextran sulfate are considered “heparin-like" for purposes of the invention.
- Naturally occurring amino acids can be generally classified as being polar or non-polar as follows:
- Amino acid residues can be generally subclassified into four major subclasses as follows:
- Acidic The residue has a negative charge due to loss of H ion at physiological pH and the residue is attracted by aqueous solution so as to seek the surface positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium at physiological pH.
- Neutral/polar The residues are not charged at physiological pH, but the residue is attracted by aqueous solution so as to seek the outer positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium.
- Amino acid residues can be further subclassified as cyclic or noncyclic, and aromatic or nonaromatic, self-explanatory classifications with respect to the side chain substituent groups of the residues, and as small or large.
- the residue is considered small if it contains a total of 4 carbon atoms or less, inclusive of the carboxyl carbon. Small residues are, of course, always nonaromatic.
- subclassification according to the foregoing scheme is as follows:
- Acidic Aspartic acid and Glutamic acid
- Neutra1/non-po1ar/s a11 Alanine
- Neutral/non-polar/large/nonaromatic Valine, Isoleucine, Leucine, Methionine;
- Neutral/non-polar/large/aromatic Phenylalanine and Tryptophan.
- the gene-encoded amino acid proline although technically within the group neutral/non-polar/large/ cyclic and nonaromatic, is a special case due to its known effects on the secondary conformation of peptide chains, and is not, therefore, included in this defined group, but is included as a group of its own.
- amino acid substitutions for those encoded in the gene can also be included in peptide compounds within the scope of the invention and can be classified within this general scheme.
- Variants of the invention may include commonly encountered amino acids, which are not encoded by the genetic code, for example, j8-alanine (/3-ala) , or other omega-amino acids, such as 3-amino propionic, 4-amino butyric and so forth, ⁇ -aminoisobutyric acid (Aib) , sarcosine (Sar) , ornithine (Orn) , citrulline (Cit) , t-butylalanine (t-BuA) , t-butylglycine (t-BuG) , N-methylisoleucine (N-Melle) , phenylglycme (Phg) , and cyclohexylalanine (Cha) , norleucine (Nle) , cysteic acid (Cya) and methionine sulfoxide (MSO) . These also fall conveniently into particular categories.
- Sar and 0-ala are neutral/non-polar/small;
- t-BuA, t-BuG, N-Melle, Nle and Cha are neutral/ non-polar/large/nonaromatic;
- Orn is basic/noncyclic
- Cya is acidic; Cit, Acetyl Lys, and MSO are neutral/polar/ large/nonaromatic; and
- Phg is neutral/non-polar/large/aromatic.
- omega-amino acids are classified according to size as neutral/non-polar/small (/3-ala, i.e., 3-aminopropionic, 4-aminobutyric) or large (all others) .
- Serine Proteases and their Inhibitors Although originally named for their mechanism of action, members of the serine protease family also show significant sequence and structural homology. Some serine proteases are very specific, cleaving only certain peptide bonds of a specific target protein while others are very nonspecific, degrading multiple target proteins into small peptides.
- Serine proteases are regulated at many levels. Some are synthesized as inactive proenzymes and are activated only during specific events and at specific locations. This allows the body to respond rapidly to a physiological perturbation by activating an already present reservoir of proteolytic activity. Coagulation, for example, is carried out when circulating proenzymes such as Factor X and prothrombin are sequentially activated in response to injury resulting in a cascade of clotting activity. In addition, proteolytic activity is often localized to specific sites, such as receptor binding sites which can cause high local concentrations of protease or proenzyme ready for activation. Once activated, it is extremely important that proteolytic activity be confined both spatially and temporally.
- serpins serine E rotease inhibitors
- Serpins all contain an inhibitor domain with a reactive peptide bond defined on either side by the variables P j and Pi• .
- the amino acids are referred to as P j , P 2 , P 3 , etc.
- P j ' the amino acids
- P 2 ' the amino acids
- P 3 the amino acids
- Protease nexin-1 is a member of the serpin family. PN-1 is produced by many different cell types including fibroblasts, glial cells, platelets and microphages. PN-1 is secreted by cells into the extracellular environment where it binds to and inhibits target serine proteases. PN-1-protease complexes then bind back to specific cell surface receptors where they are internalized and degraded.
- PN-1 is very similar, both structurally and functionally to antithrombin (AT-III) .
- AT-III is the primary plasma inhibitor of blood coagulation.
- the inhibition of thrombin by AT-III in plasma is normally very weak but is accelerated significantly by the presence of heparin or by other mucopolysaccharides on the endothelial lining of blood vessels.
- the therapeutic value of heparin as a blood "thinning" agent is due to its enhancement of AT-III activity.
- PN-1 has a high affinity heparin binding site and inhibits thrombin much more rapidly (50-100 fold) in the presence of heparin.
- PN-1 has therapeutic potential as an anticoagulant.
- PN-1 differs from AT-III in a number of ways. Unlike AT-III, PN-1 is also a good inhibitor of the fibrinolytic enzymes urokinase and plasmin, as well as trypsin. Furthermore, PN-1 is not found in significant quantities in plasma and may function primarily in the tissues. The high affinity heparin binding site of PN-1 serves to localize it to connective tissues and cells which contain sulfated proteoglycans on their surface and surrounding extracellular matrix. Thus PN-l , s primary role seems to be in regulating proteolytic activity in tissues as opposed to blood. Further evidence for the role of PN-1 is found by the fact that it is present in brain tissue and may be involved in peripheral nerve regeneration and neurite extension.
- PN-1 inhibits serine proteases can be measured by the second order association rate constant (k ⁇ ) as previously described in Bieth, J.G. (Bull. Euro. Phvsiopath. Resp. (1980) .16.:183-195) , and reported by Scott et al. (J. Biol. Chem. (1985) 260:7029-7034) . both of which are incorporated herein by reference to disclose and explain the meaning of the rate association constant.
- k ⁇ s equal to or greater than 1 x 10 5 M ⁇ S "1 for a particular protease-inhibitor reaction is considered to be physiologically significant (Travis and Salveson Ann. Rev. Biochem.
- the k ⁇ or rate association constant has inverse-mole-seconds as its units, and the larger the k ⁇ s , the more rapid the inhibition. Accordingly, a ⁇ value is always given as a value with respect to a particular enzyme and is zero if there is no inhibition of the enzyme.
- protease inhibitor reactions such as elastase- ⁇ -1 antitrypsin and plasmin- ⁇ -2-antiplasmin occur with rate constants as high as 1 x 10 7 M ⁇ S" 1 or greater.
- the thrombin-PN-1 reaction occurs at a similar high rate in the presence of heparin.
- Figures 1 and 2 respectively, show the amino acid sequence of PN-l ⁇ and PN-l/S.
- the ⁇ and ⁇ forms differ by the substitution of thr 310 -gly 311 in PN-lS for arg 310 in PN-l ⁇ .
- the "P j " site (arginine at position 345 for PN-l ⁇ and 346 for PN-1/3) has been confirmed by sequencing of the peptide fragment released from PN-1 upon dissociation of complexes with thrombin.
- PN-1 normally inhibits only enzymes which cleave at arginine (the P ! residue) , such as thrombin, plasmin, trypsin, plasminogen activators, and plasma kallikrein.
- proteases are synthesized at relatively high levels in their inactive proenzyme forms and are only activated during specific events.
- coagulation is carried out when circulating proenzymes such as Factor X and prothrombin are sequentially activated in response to an injury. This activation results in a cascade of clotting activity.
- Proteolytic activity is often localized to specific sites such as receptor binding sites. Once a proteolytic enzyme is activated, it is extremely important that the enzyme activity be confined both spatially and temporally. Such confinement is in part brought about by the inhibitory effect of serpins. All serpins contain an inhibitor domain with a reactive peptide bond defined on either side by P j and P ⁇ residues.
- the ⁇ >i residue (such as arginine at position 345 for PN-l ⁇ and 346 for PN-1/3) is recognized by the substrate binding pocket of the target protease.
- the protease Upon recognition of the "reactive" site (of the inhibitor by the protease) the protease attacks the reactive peptide bond of the inhibitor as if it were a normal substrate.
- serpin hydrolysis of the peptide bond and release of the protease does not proceed to completion.
- the normal deacylation step is so slow that the reaction becomes essentially irreversible and the protease becomes trapped with the inhibitors in a stable, covalent, equal molar complex.
- the P j residue is the predominant determinant residue recognized by the substrate binding pocket of the target protease, alteration of this residue can alter the protease specificity of the inhibitor entirely or substantially change the degree of the inhibitory effect obtainable.
- Residues near the P, residue i.e., P 4 -P 4 '
- P 4 -P 4 ' also contribute to protease specificity. Accordingly, alteration of these residues can also lead to modified inhibitory effects.
- Amino acid sequences, active sites and biochemical activity of a number of natural proteins and in particular natural serpins are known. It is also known that some proteins have a high degree of activity with respect to a certain protease, whereas another protein will have virtually no activity with respect to that protease.
- the present inventors noted this information and deduced that it might be possible to change the protease inhibitory activity of a particular protein, in a directed manner, by replacing its active site with the active site of another protein having a completely different activity with respect to that protease.
- one can create a variant of the invention by attaching to a first protein, the receptor binding region of a second protein.
- the methodology of the present invention makes it possible to make certain logical deductions and create a specific variant with a relatively high expectation of not only changing the activity (e.g. binding affinity) of the protein, but changing it in a specific and directed manner.
- a first protein might be known to have virtually no binding affinity with respect to a given receptor and a second protein might have very high binding affinity with respect to that receptor.
- a receptor can be any protein or a portion thereof, ligand, cell surface area or molecule.
- uPA urokinase-type plasminogen activator
- a variant which would (1) bind to activated endothelium cells and (2) inhibit uPA-plasmin would be useful in preventing and/or reducing inflammation at a particular site.
- Tumor cell invasiveness is also dependent upon the uPA-plasmin system as shown in tumor cell metastasis model systems (Ossowski and Reich, 1983; Hearing, et al., 1988) and extracellular matrix degradation and basement membrane invasion (Gergman, et al., 1986; Mignatti, et al., 1986; Reich, et al., 1988; Cajot, et al, 1990).
- the levels of uPA are significantly higher in human breast cancer tissues than in normal tissues.
- Increased amounts of uPAR correlate with increased invasiveness of malignant cells in model systems (Ossowski, 1988; Hearing, et al., 1988).
- Agents which block the proteolytic activity of uPA or plasmin may protect against extracellular matrix degradation and basement membrane invasion and aid in preventing inflammation.
- agents which block the interaction of urokinase with the urokinase receptor (uPAR) might block metastasis.
- a variant protein of the present invention could be designed to block the urokinase receptor and inhibit urokinase.
- a variant could be produced which combined the ability to block the urokinase receptor with the ability to inhibit urokinase and plasmin, and thereby have an effect on alleviating or preventing inflammation. Such a variant would be more effective in reducing or preventing inflammation than would either protein by itself.
- the variant By making use of the urokinase receptor binding ability of the variant, the variant will localize to the desired specific site of extracellular matrix degradation, specifically preventing further degradation by inhibiting enzymes and preventing the binding of enzymes which cause degradation, thereby having a dual effect on alleviating or preventing inflammation.
- a chimeric protein of the present invention To produce a chimeric protein of the present invention the central role of uPA and uPAR in cancer invasion and inflammation were recognized. With this information in mind it was understood that the present invention should provide a chimeric protein which would interfere with the binding of uPA to uPAR and inhibit both uPA and plasmin generated at sites of cellular invasion.
- the receptor binding region of uPA has been localized to the 135 residue amino-terminal fragment (ATF) .
- ATF 135 residue amino-terminal fragment
- This region i.e. ATF
- PN-1 blocks tumor cell-mediated extracellular matrix degradation and tumor cell migration in vitro, in that PN-1 inhibits the uPA-plasmin system.
- the present invention provides a chimeric protein consisting of the amino- terminal fragment of uPA and PN-1 (ATF-PN1) . Due to the presence of the ATF portion, this chimeric protein has a high affinity to sites of cellular invasion; and due to the PN-1 protein it inhibits uPA and plasmin.
- Type I Variant This aspect of the invention involves the manipulation of the amino acid sequence of the PN-1, so that the reactive site is in some way altered, to change the protease specificity or the degree of inhibitory effect of PN-1 on serine proteases. More specially, the present invention involves substituting one or more amino acids within protease nexin-1 and/or deleting or adding amino acids to the sequence of protease nexin-1 in order to obtain an effect on the reactive site of protease nexin-1 so that the protease specificity of protease nexin-1 and/or the degree of inhibitory effect of protease nexin-1 on a serine protease is changed.
- the change in protease specificity or degree of inhibitory effect is obtained by substituting an amino acid at the P j , P 2 , P 3 , P or, alternatively, R ⁇ , P 2 ', P 3 ', P 4 ' sites.
- the invention involves substituting one or both of the "Pj" site arginine residue or "P j •" site serine residue with a different residue resulting in PN-1 variants with radically different protease specificities and/or inhibitory effects on particular serine proteases.
- the PN-1 variants of the invention can also be described in terms of their functionality. Importantly, some of the PN-1 variants of the invention are capable of inhibiting elastase. Within this general group are PN-1 variants wherein the ability to inhibit elastase is greatly enhanced in the presence of heparin and/or heparin-like compounds. Another group of PN-1 variants of the invention include PN-1 variants which have an enhanced ability to inhibit serine proteases as compared with PN-1. The PN-1 variants of the invention are designed to inhibit serine proteases such as urokinase. Factor Xa plasmin, kallikrein.
- Functional objectives of the invention such as the production of a compounds which inhibit serine proteases such as elastase and whose ability to inhibit such is enhanced in the presence of other compounds such as heparin, are obtained, in general, by manipulating DNA.
- the DNA encoding an enzyme is manipulated by including within the DNA a sequence of DNA which encodes a substrate for a particular serine protease.
- the recombinant DNA is then expressed to produce a variant of the invention which will include a substrate for the particular serine protease. In that the substrate is present, the activity of that serine protease can be specifically inhibited by the variant while the variant maintains its natural biological activity.
- PN-1 Variants Active Site Manipulation
- Type I Variants Single Site Mutations
- the arginine residue is a polar, basic amino acid. Substitution of the polar arginine with a non-polar residue has a dramatic effect on the degree of serine protease inhibition obtainable.
- the R345I variant i.e., isoleucine has been substituted for arginine a position 345 of PN-l ⁇
- the NCY2010 variant is a good inhibitor of neutrophil elastase activity. This is surprising when it is noted that native fibroblast PN-1 has no inhibitory effect on elastase, and in fact is a substrate for elastase.
- NCY2010 The activity of NCY2010 should be viewed with the understanding that the relative efficiency at which protease inhibitors (such as the PN-1 variants of the invention) inhibit serine proteases are measured by a known standard. That standard is the second order association rate constant (k, ⁇ ) as described in (Bieth, J.G., Bull. Euro. Physiopath. Resp. (1980) 16:183-195) and reported by Scott et al. (J. Biol. Chem. (1985) 260:7029-7034) . both of which are incorporated herein by reference to disclose second order association rate constants.
- k, ⁇ the second order association rate constant
- a value for k ⁇ equal to or greater than 1 x 10 5 M ⁇ S "1 for a particular protease-inhibitor reaction is considered to be physiologically significant (Travis and Salveson Ann. Rev. Biochem. (1983) 5J2:655-709) , incorporated herein by reference to describe the significance of rate constants.
- Many physiologically important protease-inhibitor reactions such as elastase- ⁇ -1-antitrypsin and plasmin- ⁇ -2-antiplasmin occur with rate constants as high as 1 x 10 7 M ⁇ S "1 or greater.
- the thrombin-PN-1 reaction occurs at a similar high rate, or faster, in the presence of heparin.
- Native PN-1 has essentially no effect with respect to inhibiting the activity of elastase.
- the R345I variants of the present invention clearly provide not just a new biological activity for the serpin, i.e., its ability to inhibit elastase, but clearly provide an extremely potent elastase inhibitor.
- the ability of the R345I variants to inhibit elastase to such a degree was in itself a surprising finding. However, it was clearly unexpected to find that, in addition to providing such a potent elastase inhibitor, these variants had still further increased potency with respect to inhibiting elastase while in the presence of heparin.
- Variants of the invention are clearly capable not only of providing improved potency with respect to acting as elastase inhibitors, but of providing such activity site-specifically in that their activity is greatly enhanced in the presence of heparin, heparin-like compounds or other related mucopolysaccharides normally found in the endothelial lining of blood vessels.
- heparin a range of sulfated proteoglycans such as other heparin-like compounds normally found on the surface and surrounding extracellular matrix would provide not only increased potency with respect to the ability of the variants of the invention to inhibit elastase but provide site-specific activity due to the affinity of these variants to heparin and heparin-like compounds.
- the inhibitory effect of the R345I variant on elastase is increased approximately two orders of magnitude in the presence of heparin. It can be readily determined that "P ! " variants with non-polar residues such as valine substituted for the polar arginine residue could be used as a heparin activatable inhibitor in order to treat individuals suffering from elastase-related diseases such as emphysema, congenital ⁇ -1-antitrypsin deficiency, inflammation and septic shock.
- Non-polar residues which can be used include G, A, V, L, I, M, F and W, and more preferably (due to "R" group structures similar to valine) G, A, V and L, and most preferably I.
- the present invention encompasses PN-1 variants which are capable of acting as potent elastase inhibitors. More specifically, the invention encompasses such PN-1 variants which act as elastase inhibitors and further wherein the ability to inhibit elastase is greatly increased in the presence of heparin and heparin-like materials. Still more specifically, the invention encompasses PN-1 variants which act as elastase inhibitors and which variants have their ability to inhibit elastase increased 10 fold or more in the presence of heparin, preferably 50 fold or more in the presence of heparin and more preferably 100 fold or more in the presence of heparin.
- Useful formulations of the invention include PN-1 variants formulated in pharmaceutical compositions along with heparin and heparin-like compounds such as various sulfated polysaccharides or proteoglycans. It is particularly preferred if the heparin-like compounds are highly sulfated, thus providing high negative charges.
- P j variants of the invention which include non-polar residues such as valine substituted for the polar arginine can be used to treat individuals due to the ability of these P j variants to inhibit the activity of elastase.
- other proteases such as urokinase and plasmin which are inhibited by PN-l are not heparin activatable.
- the P j variants of the present invention are e fective in inhibiting elastase due to the cationicity of elastase which promotes its binding to heparin which is anionic.
- the active site should be substituted with other residues which are non- polar and have similar "R" groups in order to have a reasonable expectation of similar activity.
- PN-l Variants The sequence of PN-l ⁇ and PN-1 / 8 are given in Figures 1 and 2 respectively. Further, factors describing the characteristics of both have been put forth above. Prior to the present disclosure, variants of the invention such as elastase inhibitors of any PN-l were not known. Further, it was not known whether any such variants would provide any activity, let alone the type of activity obtained. In fact, elastase cleaves native PN-l. This cleavage inactivates PN-l toward thrombin and other proteases.
- PN-l could be changed into an even better substrate for elastase, leading to even quicker inactivation of PN-l.
- the present invention not only provides variants wherein active sites have been replaced, but shows that such variants have activity and that the activity is substantially different from the activity of the original PN-l. Now that a number of variants and their activity have been shown, it can be seen that still other variants which might possess activity can also be produced. In connection therewith, it is postulated that variants can be produced wherein substitution is made at both the P j and P j ' sites. Such double substitutions could be put forth in a variety of different ways.
- One approach to producing such variants is to substitute one of the sites with a residue which is substantially different from the residue present such as including a non-polar residue in place of a polar residue while substituting the other site with a residue which is substantially similar to the residue present there both in terms of being polar or non-polar and in terms of having a similar "R" group.
- Another approach is to substitute both sites with residues which are substantially different from the original residues.
- Yet another possible means for producing variants would be to use either of the above-suggested strategies in combination with substituting other sites. A variety of such substitutions will occur to those skilled in the art upon reading this disclosure. What is important is that the resulting variant continued to provide activity. The ability of the variant to provide activity will depend on the substrate specificity. Accordingly, the present invention is intended to encompass single, double and multiple substitutions of the residues to provide variants which continue to have activity with respect to a given protease or gain substantial activity with respect to another protease.
- the PN-l variants which have activity are variants which have (1) substantially increased potency with respect to inhibiting tPA, urokinase, and/or other related enzymes; (2) substantially increased potency with respect to inhibiting elastase; or most preferably (3) substantially increased potency with respect to inhibiting elastase and which potency is still further increased dramatically in the presence of heparin.
- the present invention has demonstrated that it is possible to produce PN-l variants which inhibit elastase and has further demonstrated that it is possible to produce such variants which not only inhibit elastase, but have substantially increased potency to inhibit elastase in the presence of heparin others skilled in the art of such inhibitors will be able to deduce other variants which are intended to be within the scope of the present invention.
- protease nexin-1 variants of the invention are listed in Table 2 along with "indication" of the variant.
- the above examples 1-81 represent the substitution at different sites within the active site of PN-l.
- record nos. 2-21 represent a substitution at the P j position of PN-l.
- the indication "WT" is provided to indicate the naturally-occurring or wild-type sequence produce via CHO cells.
- the examples could be continued to include all 20 amino acid substitutions at each position within the active site, that is, all 20 naturally-occurring amino acids could be substituted, using site-directed mutagenesis, at positions P,, P 2 , P 3 , P 4 , P j • , P 2 ! , P 3 « , and
- Type I variants it is possible to produce individual type I variants using site-directed mutagenesis. However, it is also possible to produce large numbers of Type I variants at the same time. For example, it is possible to produce the 64 million different variants simultaneously wherein all of the 20 naturally occurring amino acids are substituted at all 8 positions. Such can be carried out using a phage display synthesis methodology as disclosed within U.S. patent 5,223,409 issued June 29, 1993. Further, the chemical synthesis methodology disclosed within U.S. patent 5,010,175 issued April 23, 1991 can be used to produce such large mixtures of variants.
- any of the variants of the present invention can be tested by comparing the variants with a panel of proteases and determining their second-order rate constants with respect to the different proteases. Such tests have been carried out with an exemplary number of Type I variants, and the results are described below in Tables 1A through II. TABLE 1A Wild-type fCHO PN-l) NCY 2000
- Type II variants of the invention are produced in a manner similar to Type I variants. However, the active site of PN-l is modified in a manner so that it matches the sequence of the active site of another protease, and preferably another serpin. Examples of Type II variants of the present invention include the following:
- Type II variants This table is meant as an example and should not be considered limiting of Type II variants of the invention.
- the same methodology referred to above with respect to Type I variants can be used in the production of Type II variants. Further, the methodology disclosed within the above-cited patents (incorporated herein by reference) can be used to produce Type II variants.
- the methodology is modified only by first determining the active site of another serpin. After determining the amino acid sequence of the active site of a different serpin and studying the activity of that different serpin it is possible to produce a Type II variant having a particular and desired changed activity as compared with the naturally occurring PN-l.
- NCY 2202 particularly in the presence of heparin is analogous in some ways to that of NCY 2322 in that both inhibit catheprin G but not elastase. This is completely unexpected due to the similar substrate specificity.
- Type III Variants Incorporation of a Substrate Sequence
- Type III variants of the invention are produced by first determining the substrate sequence of a protease.
- the substrate sequences of some proteases which are known and which would be useful in connection with the present invention are put forth below in Table 3A. TABLE 3A
- PROTEASE substrate sequence Thrombin D-Phe-Pip-Arg-pNA Ts-Gly-Pro-Arg-pNA Factor Xa bz-Ile-Glu( ⁇ OR)-Gly-Arg-pNA cbo-D-Arg-Gly-Arg-pNA
- Urokinase Glu-Gly-Arg-pNA Bz-Ala-Gly-Arg-pNA tPA (D/L)-Ile-Pro-Arg-pNA Cl-esterase z-Val-Gly-Arg-pNA Kallikrein (D/Bz)-Pro-Phe-Arg-pNA Neutrophile elastase Glu-Pro-Val-pNA Ala-Ala-Pro-Val-pNA
- substrate sequences can be determined by determining the best artificial small molecule peptide substrates (i.e. Ala-Ala-Pro-Phe-pNA) as determined by k ⁇ and k ⁇ , or by examining the sequence of natural protein substrates (e.g. fibrinogen for thrombin) .
- Type IV variants of the invention are quite different from all of the other variants in that the amino acid sequence may be the same as the naturally- occurring protein or different therefrom.
- Type IV variants may be generated by covalently binding (i.e., coupling) PEG to any protein, protein fragment, or peptide in general when increased biological stability is desired.
- proteins, protein fragments, and peptides which are useful in therapeutic applications, such as serine protease inhibitor proteins, growth factors, and cytokines.
- the proteins PN-l, human growth hormone (hGH) , erythropoietin (EPO) , and antithrombin-III (ATIII) are of particular interest.
- Specific exemplary proteins of interest, as well as exemplary classes of proteins, which can be modified to create a Type IV variant using the methods of the invention are provided in Table 4A. TABLE 4A Exemplary Proteins and Protein Classes for Generation of Type IV Variants
- GDNF is the same protein as protease nexin-1 (PN-l) .
- Type IV variants are created by attaching polyethylene glycol to a thio group on a cysteine residue of the protein.
- the PEG moiety attached to the protein may range in molecular weight from about 200 to 20,000 MW.
- the PEG moiety will be from about 1,000 to 8,000 MW, more preferably from about 3,250 to 5,000, most preferably 5,000 MW.
- novel modified proteins can be created by attaching the polyethylene glycol to a cysteine residue within the protein.
- the protein is modified by attaching the polyethylene glycol to a cysteine residue at a position which is normally glycosylated.
- a cysteine residue is added at a position which is normally glycosylated (e.g. N-glycosylated) , and the polyethylene glycol is attached to the thio group of the added cysteine residue.
- glycosylation sites for any other member can be matched to an amino acid on the protein of interest, and that amino acid changed to cysteine for attachment of the polyethylene glycol.
- surface residues away from the active site or binding site can be changed to cysteine for the attachment of polyethylene glycol.
- the protein may be biotinylated by attaching biotin to a thio group of a cysteine residue.
- Type IV variants are as follows:
- records numbers 1 and 2 are of a general type known in the art in that the polyethylene glycol or biotin is attached to lysine position of the peptide.
- record numbers 3 and 4 are, respectively, examples wherein the polyethylene glycol or biotin are connected at a cysteine group. The importance of such is described further below.
- PEG polyethylene glycol
- adenosine deamidase L-asparaginase for treatment of acute lymphoblastic leukemia
- interferon alpha 2b IFN- ⁇ 2b
- superoxide dismutase as an anticancer drug
- streptokinase tPA
- urokinase uricase
- hemoglobin interleukins
- interferons TGF-/S
- EGF EGF
- this modification of a protein by attachment of a PEG moiety involves activating PEG with a functional group which will react with lysine residues on the surface of the protein. If the modification of the protein goes to completion, the activity of the protein is usually lost.
- Current modification procedures allow only partial PEGylation of the protein. Usually this results in only 50% loss of activity and greatly increased serum half-life, so that the overall dose of the protein required for the desired activity is lower.
- An unavoidable result of the partial modification is that there will be a statistical distribution of the number of PEG groups per protein, each PEG attached to a lysine residue. Also, there will be a random usage of lysine residues on the surface. For instance, when adenosine deaminase is optimally modified, there is a loss of 50% activity when the protein has about 14 PEG per protein, with a broad distribution of actual PEG per individual protein and a broad distribution of actual lysine residues used.
- PEG-modify other residues such as His, Trp, Cys, Asp, Glu, etc. in such a manner that activity is not lost. It is anticipated or likely that many of these residues will be at or near the active site or that these residues will not be at the surface or in sufficient number to significantly affect serum half-life, or that the modification chemistry is not specific enough for the target residue, or the chemistry is too harsh for the protein to withstand without loss of activity.
- residues can easily be determined by those skilled in the art. For instance, if a three-dimensional structure is available for the protein of interest, or a related protein, solvent accessible amino acids are easily identified. Also, charged amino acids such as Lys, Arg, Asp and Glu are almost exclusively found on the surface of proteins. Substitution of one, two or many of these residues with cysteine will provide additional sites for PEG attachment. In addition, amino acid sequences in the native protein which are recognized by antibodies are usually on the surface of the protein. These and other methods for determining solvent accessible amino acids are well known to those skilled in the art.
- Modification of proteins with PEG can also be used to generate dimers and multimeric complexes of proteins, fragments, and/or peptides which have increased biological stability potency.
- These dimeric and multimeric proteins of the invention may be naturally occurring dimeric or multimeric proteins.
- the di er or multimer may be composed of cross-linked subunits of a protein (e.g., hemoglobin).
- the dimeric and multimeric proteins may be composed of two proteins which are not normally cross-linked (e.g., a dimer of cross-linked EPO protein.
- Dimeric proteins of the invention may be produced by reacting the protein with (Maleimido) 2 -PEG, a reagent composed of PEG having two protein-reactive moieties. This PEGylation reaction with the bi-functional PEG moiety generates dimers of the general formula: R j -S-PEG-S-R 2
- R j and R 2 may represent the same or different proteins and S represents the thio group of a cysteine either present in the native Rj or R 2 protein, or introduced by site-directed mutagenesis.
- the proteins R j and R 2 may each vary in size from about 6 to 1,000 amino acids, preferably about 20 to 400 amino acids, more preferably 40 to 200 amino acids. In dimeric molecules, R j and R 2 are preferably from about 100 to 200 amino acids. Dimers and multimers of particular interest include those composed of proteins, protein fragments and/or peptides which are less than about 40,000 molecular weight.
- multimeric proteins where the proteins (represented by R j , R 2 , RJ may be the same or different can be generated.
- the proteins represented by R,, R 2 , R__ may vary in size from about
- Such multimeric proteins may be of the following general formula:
- R j represents the protein having multiple free cysteines, for example from 2 to 20 free cysteines, usually from 5 to 7 free cysteines.
- R 2 may represent a protein the same as or different from R j .
- each of the R 2 proteins attached to R j may be the same proteins, or represent several different proteins.
- the degree of multimeric cross-linking can be controlled by the number of cysteines either present and/or engineering into the protein and by the concentration of (Maleimido) 2 PEG used in the reaction mixture.
- the Maleimido-PEG+ (Maleimido) 2 -PEG reagents may be used in the same reaction with proteins for formation of couplings of proteins having simple PEG moieties as well as PEG cross-links between proteins within the complex.
- the dimeric or multimeric protein generated will have an increased half-life relative to the native, protein, due at least in part to its increased size relative to the native protein. Such larger proteins are not degraded or cleared from the circulation by the kidneys as quickly as are smaller proteins.
- Dimeric and multimeric proteins may be generated by reaction with Maleimido-PEG or (Maleimido) 2 -PEG.
- Exemplary proteins for dimeric and/or multimeric complex formation using the method of the invention include PN-l, PN-l variants, hemoglobin, and erythropoietin (EPO) , as well as any of the proteins or members of the protein classes exemplified in Table 4A.
- the protein generated by the method of the invention is a PEGylated cross-linked complex of the "a" and "b" chains of hemoglobin, multimeric complexes of hemoglobin having intermolecular and/or intramolecular cross-links may also be generated by the subject method.
- the method of identifying cysteine residues for PEG modification, and/or identifying amino acid residues to be replaced with cysteine which are subsequently modified by attachment of PEG provides for generation of a PEGylated protein which can be reasonably expected to retain most or all of the activity of the native protein.
- the sites selected for modification and/or substitution with cysteine are selected on the basis of the structure of the protein, i.e. the selected sites are solvent accessible residues which are not involved in the active site.
- mutations located outside of the active site are generally predictable in that they generally do not change the primary activity of the protein.
- structural mutations described herein are within solvent-accessible regions of the protein (i.e. on the protein "surface") which have limited or no interaction with other residues in the protein molecule. Thus, mutations at these positions are unlikely to affect the conformation of any other amino acid in a protein.
- Type V variants of the invention are produced by fusing all or a fragment of another protein to PN-l.
- the amino terminal fragment of a protein such as urokinase is fused to PN-l in order to localize PN-l to a different receptor, i.e. to the urokinase receptor.
- a protein such as urokinase
- it is possible to fuse the amino terminal fragment of proteins such as tPA, Factor IX, Factor X, and Protein C. Examples of Type V variants are as follows:
- the type V variants of the invention can be produced in manner similar to variants of type I, II and III. However, it is more preferable to produce such variants by chemically fusing an N-terminal fragment of a different protein to the PN-l.
- Type V variants can also be produced by chemical linkage of purified preparations of both protein components. Such linkage is conveniently accomplished by using bi-functional cross-linking reagents. Methods for chemically establishing such linkages are well known to those skilled in the art. Specific variants which might be produced in this manner include variants produced by fusing PN-l to any one of: EGF; Factor IX; Factor X; and APC.
- the method of PEGylation of the invention is intended to be a general procedure and as such is applicable to any protein to increase solubility, circulating half life and/or to decrease immunogencity. Testing Type V Variants
- Type V variants of the invention are chimeric proteins wherein PN-l is covalently bound to another protein.
- the same panel of proteases indicated above were used to test one of the Type V variants of the invention, and the results are put forth below.
- P j variants with non-polar residues such as valine substituted for the polar arginine residue could be used as heparin activatable inhibitors.
- Such inhibitors could be used to treat individuals suffering from elastase-related diseases.
- such variants could be used to treat emphysema, congenital ⁇ -1-antitrypsin deficiency, inflammation, arthritis and septic shock.
- chimeric proteins, PN-l variants, and/or cysteine-PEGylated versions of these proteins of the invention is the inclusion of such within various topical formulations such as creams or gels, or a combination of such formulations, with various bandages for application to wounds to aid in wound healing and decrease inflammation at wound sites.
- injectable formulations containing the chimeric proteins, PN-l variants, and/or cysteine-PEGylated versions of these proteins of the invention may be injected directly into inflamed joints or other inflamed areas of the body in order to decrease the inflammation.
- the formulations of the invention may be used prophylactically by providing the chimeric proteins, PN-l variants, and/or cysteine-PEGylated versions of these proteins to a particular site which may be subjected to trauma, (such as in surgery) , and thus inflammation, to prevent the inflammation from occurring.
- the pharmaceutical compositions containing the chimeric proteins, PN-l variants, and/or cysteine-PEGylated proteins of the invention will be formulated in a non-toxic, inert, pharmaceutically acceptable aqueous carrier medium, preferably at a pH of about 5 to 8, more preferably 6 to 8, although the preferred pH of the pharmaceutical composition may vary according to the protein employed and condition to be treated.
- cysteine-PEGylated proteins and pharmaceutical compositions containing these protein.
- PEGylation of proteins generates proteins which are ready for immediate therapeutic use (i.e. do not require reconstitution) , have increased solubility and have an increased half-life and are reduced in immunogenicity and antigenicity relative to the unmodified protein (Nucci et al. 1991 Adv. Drug Delivery res . 6:133-151).
- the increased half- life of PEGylated proteins decreases the amount of protein needed for an effective dosage, reduces the number and frequency of administrations required, and decreases the patient's exposure to the protein, thus decreasing the potential for allergic reactions, toxic effects, or other side effect.
- Exemplary proteins for which an increase half-life has effected by PEGylation of the protein include: hGH, insulin, interferon-alpha2A (IFN-alpha-2A) , interferon-alpha2B (IFN-alpha-2B) , tPA, EPO, G-CSF, antigen E, arginase, asparaginase, adenosine deaminase, batroxobin, bovine serum albumin, catalase, elastase, factor VIII, galactosidase, alpha-galactosidase, beta-glucuronidase, IgG, honeybee venom, hemoglobin, interleukin-2, lipase, phenylalanine ammonia lyase, alphaj-proteinase inhibitor, pro-urokinas
- PEGylated proteins may be administered for the treatment of a wide variety of diseases. Exemplary disease conditions and the proteins useful in treatment of these diseases are provided in Table 6A.
- Enzyme Deficiency Endotoxic Shock/Sepsis adenosine deaminase Bactericidal/permeability Purine nucleotide increasing protein phosphorylase Lipid-binding protein (LBP) Galacto ⁇ idase ff-glucuronidase
- Phenylalanine ammonia lyase G-CSF Phenylalanine ammonia lyase G-CSF
- GCSF Granulocyte colony Thrompoietin stimulating factor
- Urokinase (native or chimeric) ⁇ -antitrypsin antithrombin-111
- chimeric proteins, PN-l variants, and cysteine-PEGylated proteins may be delivered within the formulations and by the routes of administration discussed above.
- the particular formulation, exact dosage, and route of administration will be determined by the attending physician and will vary according to each specific situation. Such determinations are made by considering such variables as the condition to be treated, the protein to be administered, the pharmacokinetic profile of the particular protein, as well a various factors which may modify the effectiveness of the protein as a drug, such as disease state (e.g. severity) of the patient, age, weight, gender, diet, time of administration, drug combination, reaction sensitivities, tolerance to therapy, and response to therapy.
- disease state e.g. severity
- cysteine-PEGylated proteins are used in the pharmaceutical composition
- the clearance rate i.e. the half-life of the protein
- the daily regimen should generally be in the range of the dosage for the natural, recombinant, or PEGylated protein. Normal dosage amounts may vary from 0.1 to 100 micrograms, up to a total dose of about 1 g, depending upon the route of administration.
- PEGylated proteins include: hGH, insulin, interferon-alpha2A, interferon-alpha2B, tPA, EPO, G-CSF, and a hepatitis B vaccine which contains PEGylated proteins (Nucci et al. ibid) .
- PN-l is not found in significant quantities in plasma and may function primarily in tissues.
- the high affinity heparin binding site of PN-l appears to serve to localize PN-l to connective tissues and cells which contain sulfated proteoglycans on their surface and surrounding extracellular matrix.
- the primary role of PN-l seems to be in regulating proteolytic activity in tissues as opposed to blood.
- PN-l is found in brain tissue
- another aspect of the invention involves delivering formulations of the invention containing PN-l variants or chimeric proteins in order to facilitate peripheral or central nerve regeneration.
- Formulations, routes of administration and dosages for use of PN-l in the treatment of inflammation and wounds are described in USPNs 5,206,017; 5,196,196; and 5,112,608; each of which are incorporated herein by reference to the extent that such methods of treatment using PN-l are described.
- chimeric proteins or protease nexin-1 and its variants by oral delivery systems.
- Such proteins are generally digested in the GI tract (unless formulated with special carriers) and do not enter the cardiovascular system in their original forms due to such digestion.
- Chimeric proteins, PN-l variants, and/or cysteine-PEGylated versions of these proteins can be administered by any type of injection, such as intramuscular or intravenous, thus avoiding the GI tract.
- Other modes of administration include transdermal and transmucosal administrations provided by patches and/or topical cream compositions.
- Transmucosal administrations can include nasal spray formulations which include the chimeric proteins, protease nexin-1 variant, and/or cysteine-PEGylated proteins within a nasal formulation which contacts the nasal membranes and diffuses through those membranes directly into the cardiovascular system. PEGylated proteins may have an increased ability to cross membranes and thus may enter the body more easily.
- Formulations which include the chimeric proteins, PN-l variants within aerosols for intrapulmonary delivery are also contemplated by this invention, as are intraocular delivery systems wherein the chimeric proteins or PN-l variants are included within ophthalmic formulations for delivery in the form of eye drops.
- the formulations can be designed to provide the chimeric proteins or PN-l variants systemically or to a particular site. Further, the formulations can be designed so as to provide the chimeric proteins or PN-l variants as quickly as possible or in a sustained release or timed released manner.
- topical formulations could be created whereby the chimeric proteins or PN-l variants of the invention were incorporated or disbursed throughout topical polymer formulations capable of slowly releasing the chimeric proteins or PN-l variants to a wound site in order to continually aid in wound healing and in preventing inflammation.
- chimeric proteins, PN-l variants, and/or cysteine-PEGylated protein can be administered in a variety of different manners in order to introduce the chimeric proteins, PN-l variants, and/or cysteine-PEGylated protein into the cardio vascular system.
- the chimeric proteins, PN-l variants, and/or cysteine-PEGylated proteins are administered for a variety of purposes which generally relate to, for example: blocking proteolytic activity; inhibition of tumor growth or metastasis; promotion of wound healing and/or nerve fiber regeneration; replacement therapy for protein-deficient states (e.g. diabetes) ; inhibition of bacterial, fungal, or viral growth; enhancement of the immune response; induction of maturation of bone marrow stem cells (e.g.
- intravenous formulations containing the chimeric proteins, PN-l variants, and/or cysteine-PEGylated versions of these proteins are useful for their anti-thrombolytic effect and therefore can be administered to aid and a prevention and/or alleviation of strokes and/or heart attacks.
- EXAMPLE A The Synthesis of PN-l PN-l was purified to homogeneity from serum-free medium conditioned by human foreskin fibroblasts in microcarrier cultures by affinity chromatography on heparin-agarose, followed by gel exclusion chromatography, as described in detail by Scott, R.W. et al., J Biol Chem (1985) 260:7029-7034. incorporated herein by reference. Of course, other chromatographic supports which contain heparin for affinity binding or other matrix such as cm sepharose or S-sepharose can also be used.
- the purified protein shows an M.. of 42-43 kd, based on sedimentation equilibrium analysis, or of 47 kd, estimated from gel-exclusion chromatography.
- the purified material shows the properties exhibited by PN-l when contained in conditioned medium, including formation of sodium dodecylsulfate-stable complexes with thrombin, urokinase, and plasmin; inhibition of protease activity; heparin-enhanced inhibition of thrombin; and cellular binding of protease-PN complexes in a heparin-sensitive reaction.
- N-terminal amino acid sequence of the isolated, purified protease nexin was determined for the first 34 amino acids to be: Ser-His-Phe-Asn-Pro-Leu-Ser- Leu-Glu-Glu-Leu-Gly-Ser-Asn-Thr-Gly-Ile-Gln-Val-Phe-Asn- Gln-Ile-Val-Lys-Ser-Arg-Pro-His-Asp-Asn-Ile-Val-Ile.
- the PN-l variants of the present invention can be synthesized by utilizing the pure PN-l which has been isolated and purified in the manner indicated above.
- the variants can be obtained by cleaving the purified PN-l protein at the P j or P j ' site and replacing the arginine, serine or both residues at that site with the desired non-polar substitute residue. After replacement of the desired residue with the desired non-polar residue, the segments can be fused utilizing protocols known to those skilled in the art.
- protocols known to those skilled in the art.
- the PN-l can be directly produced as a mature protein preceded by a Met N-terminal amino acid (which may or may not be processed, depending on the choice of expression systems) may be produced as a fusion protein to any desirable additional N-terminal or C-terminal sequence, or may be secreted as a mature protein when preceded by a signal sequence, either its own, or a heterologous sequence provided by, for example, the known signal sequence associated with the bacterial-lactamase gene or with secreted human genes such as insulin or growth hormones.
- a signal sequence either its own, or a heterologous sequence provided by, for example, the known signal sequence associated with the bacterial-lactamase gene or with secreted human genes such as insulin or growth hormones.
- Means for providing suitable restriction sites at appropriate locations with respect to the desired coding sequence by site-directed mutagenesis are well understood, and the coding sequence can thus be provided with suitable sites for attachment to signal sequence or fusion sequence, or into expression vectors.
- the protein produced may include the N-terminal Met. Modification of the protein produced either intracellularly or as secreted from such bacterial host can be done by providing the polysaccharide substances, by refolding using techniques to sever and reform disulfide bonds, or other post-translational ex vivo processing techniques.
- the cellular environment is such that post-translational processing can occur m vivo, and a glycosylated form of the protein is most likely produced.
- the recombinant cells are cultured under conditions suitable for the host in question, and the protein is recovered from the cellular lysate or from the medium, as determined by mode of expression. Purification of the protein can be achieved using methods similar to that disclosed by Scott, R.W. et al., J Biol Chem (supra) , or by other means known in the art.
- DNA segments coding for the production of PN-l have been inserted into bacterial hosts, multiple copies of the segments can, of course, be cloned by growing the bacteria.
- the segments can be extracted from the bacteria by the use of conventional methodology whereby the DNA is extracted by subjecting disrupted cells to centrifugation and then subjecting the extracted DNA to enzyme digestion, which will result in obtaining the desired segments by subjecting the digested DNA to separation processes such as gel electrophoresis and blotting.
- the segments coding for the production of PN-l can then be subjected to conventional recombinant methodologies in order to substitute codons coding for the arginine and/or serine with new codons which code for the production of the desired non-polar amino acid residue.
- Once such recombinant segments are produced they can be reinserted into vectors and hosts in the manner described above in order to obtain the production of the desired PN-l variants.
- a variety of vector and host systems known to those skilled in the art can be used.
- PN-l variants might be made by using recombinantly produced PN-l and then substituting only the desired "R” group (e.g., -OH of serine 346) with a non-polar "R” group (e.g., -CH 2 CH 2 -s-CH 3 ) to get a PN-Met 346 variant.
- R desired “R” group
- R non-polar "R” group
- plasmid expression vector In order to produce PN-l and/or PN-l variants in insect cells, the cDNA sequence must first be inserted into a suitable plasmid expression vector, such as pAC373. Appropriate restriction sites for this insertion can be created by standard site-directed mutagenesis procedures.
- a suitable expression vector include a transcriptional promoter such as the polyhedron gene promoter of pAC373, and flanking homologous sequences to direct recombination into the baculovirus genome.
- a polyadenylation signal such as the one from the polyhedron gene present in this plasmid vector, may or may not be necessary for expression of the recombinant gene.
- a marker gene such as the ⁇ - galactosidase gene of E. coli, juxtaposed to regulatory sequences including a transcriptional promoter and possibly a polyadenylation signal, may be included in the vector but is not essential for expression of a convected gene.
- a chimeric baculovirus is created by homologous recombination between the expression plasmid containing the PN-l target gene and wild type baculovirus DNA. Plasmid and wild type baculovirus DNA are co-precipitated by the calcium phosphate technique and added to uninfected Spodoptera frugiperda (Sf9) insect cells. Four to seven days following transfection, cells will exhibit a cytopathic morphology and contain the nuclear occlusion bodies typically produced by viral infection. The cell-free culture media containing both wild type and recombinant virus is harvested.
- Clonal isolates of virus can be obtained from this co-transfection stock by plaque purification on Sf9 cell monolayers overlaid with agarose.
- Candidate plaques for analysis will be identified by a plaque morphology negative for occlusion bodies. If the expression plasmid contains a marker gene such as /3-galactosidase, recombinant plaques will be indicated by the blue color produced from a chromogenic substrate such as 5-bromo- 4-chloryl-3-indolyl-b-D-galactopyranoside (X-gal) in the agarose plating medium. Picked plaques will be used for inoculation of cells in multiwell dishes.
- the resulting cell lysates and infected cell supernatants can be evaluated for expression of recombinant PN-l, using standard activity or immunological assays. Positive wells may require additional rounds of plaque purification to obtain pure recombinant virus stocks free from wild type contamination.
- Sf9 cells are adapted to growth in serum-free, low protein medium such as ExCell (J.R. Scientific) .
- Cells are collected from suspension culture by gentle centrifugation and resuspended in fresh medium containing the viral inoculum at a concentration of ten million cells per ml., using a multiplicity of infection of one virus plaque forming unit per cell. After a period of two hours, the culture is diluted five fold with fresh medium and incubated two to three days. At the end of that time, the cells are pelleted by centrifugation and the conditioned medium harvested. PN-l is purified from the cell-free supernatant by standard means.
- Variants of PN-l may be created and produced in the same manner as described above.
- PN-l produced in insect cells using a baculovirus expression system is a glycosylated protein of approximate molecular weight of 42,000 kd.
- the N-terminal amino acid sequence is identical to that of mature mammalian cell PN-l, indicating correct processing of the signal sequence.
- the specific activity vs thrombin and association kinetics, including rate enhancement effect of heparin, are indistinguishable from authentic PN-l.
- PN-l D.l Cloning of PN-l
- the cloning of PN-l and expression has been described (McGrogan, et al., (1988) Bio/Technology).
- the gene for PN-l was generated by PCR from the CHO expression vector using the following oligonucleotides: PNPCR-forward 5' TG.GAA.GGA.CAT.ATG.AAC.TGG.CAT.CTC PNPCR-reverse 5 ' TCT.TTT.GTA.TAC.TGA.TCA.GGG.TTT.GT generating an Ndel and Bell site, respectively.
- the resulting fragment was cut with Ndel and Bell and subcloned into pGEMEX-1 vector (Promega) .
- the pGEMEX E. coli expression vector contains three RNA polymerase promoters.
- the T7 promoter is positioned upstream from the gene 10 leader fragment.
- pT7-NK was cut with Ndel and BamHI to remove the gene 10 fusion protein region.
- the linear vector was isolated and ligated with the PCR- generated PN-l linear fragment, cut with Ndel and Bell, described above. This plasmid is referred to as pT7PN-l.
- the correct sequence was confirmed by sequencing the entire coding region for PN-l.
- the native signal sequence was removed using PCR and the following oligos:
- the expression of the resulting protein is expected to be intracellular, either in inclusion bodies or as soluble protein.
- the plasmid pT7PNl has an f1 ori for the production of single-stranded DNA.
- pT7PNl was transformed into the E. coli strain CJ236 for the production of ssDNA to be used as a template for site- directed mutagenesis according to the method of Kunkel (Kunkel, T.A. (1988) in Nucleic Acids and Molecular Biology (Eckstein, F. , Lilley, D.M.J. Eds.) Vol. 2, p. 124, Springer-Verlag, Berlin and Heidelberg).
- sequences found at the active site region of other serpins were grafted onto PN-l. A number of combinations must be created to determine how much of the sequence at the active site must be changed to change the specificity and kinetics.
- the P 4 to P 4 ' region is generally found to be most important, but amino acids residues outside this region can have pronounced affects on protease inhibition.
- sequences which have been found to be particularly good substrates are added to or used to replace a sequence of PN-l. Prior to making these mutants, it was not clear if these changes would ruin the inhibitory effects of PN-l and turn PN-l from an inhibitor of proteolysis into a substrate.
- optimum inhibitor sequences can be generated by using a phage display system. Since PN-l forms covalent interactions with the target protease, it is important that one is not selecting for mutants which bind more tightly than the parent PN-l molecule. Rather, one selects for PN-l variants which bind more rapidly to the target protease by allowing phage-displayed variant PN-l library to interact with the immobilized target protease for only short times. Thus, only rapid-binding variants will be selected. This is a novel application of the phage display system.
- ATA.GTA.GAC A344P;R345L;P348Q;P349V;W350R (HCII- like) 5'GAA.GAT.GGA.ACC.AAA.GCT.TCA.GAC.TTT.TTG.GCT.GAA.GGT.
- GGC.GGT.GTA.AGA.TCA.TCG.CCT.CCC.TGG A336D;A337F; T338L;T339A;A340E;I341G;L342G;A344V (fibrinogen- like, thrombin) 5 • GCA.ACA.ACT.GCA.ATT.ATC.GAG.GGA.AGA.TCA.TCG.CCT
- L342I;I343E;A344G (Factor Xa) 5•ACA.ACT.GCA.ATT.CTC.GAG.CCA.GTA.TCA.TCG.CCT.CCC I343E;A344P;R345V (elastase, cathepsin G)
- JM109 (DE3) contains a chromosomal copy of the gene which codes for T7RNA polymerase under the control of the inducible lac promoter.
- JM109 (DE3) containing pT7PN-l (or a variant of PN-l) was grown overnight in 2xYT + 0.2% glucose + 100 mg/ml carbenicillin at 28-32°C. Low temperature and high nutrient containing solution is helpful in generating productive innoculants.
- the inoculum was diluted 1:250 to 1:500 and grown to OD ⁇ -l in a shake flask or -50 in a fermentor at 26-37°C, and induced with IPTG at 0.1-1.0 mM for 4-16 hours.
- the bacteria were collected by centrifugation, resuspended in 10 mM TRIS, pH 8, 1 mM EDTA, and disrupted by high pressure homogenization. Inclusion bodies were collected by centrifugation, washed with 1 M NaCl, 0.05% triethylamine, and the protein refolded from a 6 M guanidine solution by rapid dilution.
- PN-l was purified by capture on Fasts sepharose and eluted with 0.6 M NaCl, diluted to 0.25 M NaCl and passed over FastQ sepharose to remove endotoxin and recaptured on Fasts sepharose and eluted with 0.6 M NaCl or a gradient of 0.25 to 1 M NaCl.
- PN-l can be generated in a soluble form within E. coli by adjusting the fermentation conditions. This procedure provides a greater yield of soluble PN-l as the fermentation temperature is decreased from 37°C to 26°C with a concomitant loss in inclusion body material. This is quite an unexpected finding, since PN-l is bactericidal when native PN-l is added to E. coli.
- the cell supernatant from the disruption step was clarified by centrifugation and filtration or by treatment with polycations such as polyethyleneimine or Biacry ⁇ TM followed by centrifugation and filtration, and the soluble protein was purified as above.
- the generation of soluble material has many advantages: there is more certainty that the protein is correctly folded, there are no refolding steps, there is greater reproducibility from batch to batch.
- PN-l The production of PN-l was about 50 mg per gram of cell paste. This corresponds to about 50 mg per liter of production at a cell density of 1 OD ⁇ or up to 2.5 grams of soluble PN-l per liter of fermentation. This represents a substantial advance in the state of the art of PN-l production.
- Refolded or soluble protein was tested for capacity to inhibit thrombin in a standard assay. Briefly, serial 2-fold dilutions of PN-l variant were added to microtiter plate wells (50 ⁇ l/well) , followed by 50 ⁇ l of a 30 ⁇ g/ml heparin solution, followed by 1 NIH unit of thrombin in 50 ⁇ l. These were allowed to incubate at 25°C for 15 minutes. Residual thrombin activity was measured by the addition of 50 ⁇ l S-2238 (Kabi Pharmaceuticals) at 0.625 mg/ml.
- PN-l variants were tested for their ability to inhibit urokinase using the substrate S-2444, plasmin using the substrate S-2390, tPA using the substrate S2288, Factor Xa using the substrate S-2222 or S-2765, kallikrein using the substrate S-2302, human neutrophil elastase using s-AAPV-pna (Sigma) , cathepsin G using s-AAPF-pna (Sigma) in a similar manner, with or without the addition of heparin.
- the second-order rate association constants were determined for appropriate inhibitors-proteases combinations by combining equal-molar amounts of each protein (determined by titration as above) for various times from 1 second to 4 hours (as appropriate) and following the activity loss.
- the t 1/2 was estimated from resulting curves.
- the k,, ⁇ was estimated according to the equation ln2/ [PN-l] x t 1/2 .
- the apparent first order rate constant was determined from the slope of a plot of log (normalized activity) vs time.
- the second order rate constant was calculated by dividing the apparent first order rate constant by the PN-l (or variant) concentration used.
- ATF 8 -PN1 was made by introducing a Mlul site (underlined) by site directed mutagenesis at codon 48 using the following oligonucleotide: 5'CAC.TGT.GAA.ATA.GAT.AAC.GCG.TAA.ACC.TGC.TAT.GAG. The resulting plasmid was cut with Mlul to remove a 300 bp segment and ligated. Mutagenesis of ATF-PN1
- the plasmid pT7ATF-PNl has an f1 ori for the production of single-stranded DNA.
- pT7ATF-PNl was transformed into the E. coli strain CJ236 for the production of ssDNA to be used as a template for site- directed mutagenesis according to the method of Kunkel (Kunkel, T.A. (1988) in Nucleic Acids and Molecular Biology (Eckstein, F., Lilley, D.M.J. Eds.) Vol. 2, p. 124, Springer-Verlag, Berlin and Heidelberg).
- Kunkel Kunkel, T.A. (1988) in Nucleic Acids and Molecular Biology (Eckstein, F., Lilley, D.M.J. Eds.) Vol. 2, p. 124, Springer-Verlag, Berlin and Heidelberg).
- PN-l variants of interest can be subcloned into pT7ATF-PN-l by using standard molecular biology techniques.
- the resultant plasmid was transformed into the E. coli strain JM109 (DE3) , grown to OD ⁇ -1 in a shake flask or -50 in a fermentor, and induced with IPTG at 0.1-1.0 mM for 4-16 hours at 26-37°C.
- the bacteria were collected by centrifugation, resuspended in 10 mM TRIS, pH 8, 1 mM EDTA, and disrupted by high pressure homogenization. Inclusion bodies were collected by centrifugation, washed with 1 M NaCl, 0.05 % TEA, and the protein refolded from a 6 M guanidine solution.
- ATP-PN1 was purified by capture on Fasts sepharose and eluted with 0.6 M NaCl, diluted to 0.25 M NaCl and passed over FastQ sepharose to remove endotoxin and recaptured on Fasts sepharose and eluted with 0.6 M NaCl or a gradient of 0.25 to 1 M NaCl.
- the cell supernatant from the disruption step was clarified by centrifugation and filtration, and the soluble protein was purified as above.
- Refolded or soluble protein was tested for capacity to inhibit thrombin in a standard assay. Briefly, serial 2-fold dilutions of ATF-PNl were added to microtiter plate wells (50 ⁇ l/well) , followed by 50 ⁇ l of a 30 ⁇ g/ml heparin solution, followed by 1 NIH unit of thrombin in 50 ⁇ l. These are allowed to incubate at 25°C for 15 minutes. Residual thrombin activity is measured by the addition of 50 ⁇ l S-2238 (kabi Pharmaceuticals) at 0.625 mg/ml. ATF-PNl was tested for its ability to inhibit urokinase using the substrate S-2444, or plasmin using the substrate S-2390, in a similar manner, without the addition of heparin.
- Refolded or soluble protein was tested for the ability to bind to a soluble form of the urokinase receptor as measured by ELIZA, or the ability to inhibit the binding of urokinase to the soluble urokinase receptor.
- ATF-PNl was also tested for its ability to inhibit uPA or DFP/PMFS treated uPA binding to cells such as HT1080, U937, or THP-1 expressing uPA receptor.
- Maleimido-PEG was prepared by mixing the following:
- the amount of the components above (particularly 1) and 2)) and the volume indicated may be varied.
- the difference in the ratio of methoxypolyethylene amine to GMBS can vary by up to ten to 100-fold. Normally, about a two-fold excess of 1) above to GMBS is preferred.
- various buffers may be substituted for the Caps buffer, it is important that Tris buffers are not used in this mixture, as Tris buffers will quench the reaction.
- the pH of the buffer used may vary considerably, although buffers having a pH of 10.0 are preferable over buffers having a pH of 8.0.
- the mixture above may contain up to 50% DMSO as a cosolvent. It is particularly important that the reaction mixture does not contain a reducing agent such as dithiothreitol (DTT) or /S-mercaptoethanol (/3ME) .
- DTT dithiothreitol
- /3ME /S-mercaptoethanol
- the mixture was incubated at 37°C for 30 minutes, although the reaction temperature may be as low as 4°C and the reaction time may be extended for up to one hour or more. After incubation, 12 mg of Tris free base or ethanolamine was added to the mixture to quench the NH 3 moiety. This quenching step may be omitted.
- the reacted mixture is purified by elution through a PD-10 column (G-25) (BioRad) equilibrated with 20 mM Tris (pH 7.4), 100 mM NaCl, and 0.1% Tween.
- the eluant was collected in 0.5 ml fractions and assayed for production of the Maleimido-PEG reagent by precipitation with 50% TCA.
- the resulting Maleimido-PEG (Mal-PEG) reagent is then used in to modify a selected protein by attachment of PEG to a cysteine residue(s).
- the purified protein Prior to reaction of the protein with the Maleimido PEG reagent, the purified protein was diluted to a concentration of about 200 ⁇ g/ml to 1 mg/ml in any suitable buffer which does not contain DTT or JME. Normally, the buffer was composed of 20 mM PIPES pH 6.75, 0.6 M NaCl, and 1% glycerol. Approximately 10 ⁇ l to 40 ⁇ l of the diluted protein was used for the PEGylation reaction.
- the Maleimido-PEG reagent described in section F.l was diluted in a series of 2-fold dilutions using 10 ⁇ l transfers of solution containing approximately 1 ⁇ l Maleimido-PEG in a 10 ⁇ l volume of buffer composed of 20 mM Tris pH 7.4, 0.1 M NaCl, and 0.01% Tween.
- the ratio of the maleimido-PEG to protein may be varied according to the preferred level of PEGylation of the protein desired. Up to 20-fold excess of maleimido-PEG to protein still provided for specific reaction of the reagent with cysteine residues of the protein.
- the protein and maleimido-PEG were incubated for one hour at room temperature, although this reaction may be performed at 4°C for longer periods of time.
- a sample of the reacted mixture may be analyzed by SDS-PAGE to determine the minimal amount of maleimido-PEG reagent needed for complete coupling.
- the reaction described above may be used to determine the proper ratio of Maleimido-PEG to protein, and then scaled up to produce commercially acceptable amounts of PEGylated protein.
- the amount of the components above (particularly 1) and 2)) and the volume indicated may be varied.
- the difference in the ratio of 10 and 2) can vary by up to 10 to 100 fold, although an excess of GMBS to 1) above is preferred, normally about a 2-fold excess.
- various buffers may be substituted for the Caps buffer, it is important that Tris buffers are not used in this mixture, as Tris buffers will quench the reaction.
- the pH of the buffer used may vary considerably, although buffers having a pH of 10.0 are preferable over buffers having a pH of 8.0.
- the mixture above may contain up to 50% DMSO as a cosolvent. It is particularly important that the reaction mixture does not contain a reducing agent such as dithiothreitol (DTT) or /8-mercaptoethanol (/3ME) .
- DTT dithiothreitol
- 3ME /8-mercaptoethanol
- the mixture is incubated at 37°C for 30 minutes, although the reaction temperature may be as low as 4°C and the reaction time may be extended for up to one hour or more. After incubation, 12 mg of Tris free base or ethanolamine is added to the mixture to quench the NH 3 moiety. This quenching step may be omitted.
- the reacted mixture is purified by elution through a PD-10 column (G-25) (BioRad) equilibrated with 20 mM Tris (pH 7.4), 100 mM NaCl, and 0.1% Tween.
- the eluant is collected in 0.5 ml fractions and production of (Maleimido) 2 -PEG is assayed by precipitation with 50% TCA.
- the resulting (Maleimido) 2 -PEG (Mal-PEG) reagent is then used in to modify a selected protein by attachment of PEG to a cysteine residue(s) .
- the purified protein Prior to reaction of the protein with the (Maleimido) 2 -PEG reagent, the purified protein (e.g. a PN-l mutant containing a cysteine residue at position 99) is diluted to a concentration of about 200 ⁇ g/ml to 1 mg/ml in any suitable buffer which does not contain DTT or /3ME.
- the buffer is composed of 20 mM PIPES pH 6.75, 0.6 M NaCl, and 1% glycerol. Approximately 10 ⁇ l to 40 ⁇ l of the diluted protein is used for the PEGylation reaction.
- the (Maleimido) 2 -PEG reagent described in section F.l is diluted in a series of 2-fold dilutions using 10 ⁇ l transfers of solution containing approximately 1 ⁇ l (Maleimido) 2 -PEG in a 10 ⁇ l volume of buffer composed of 20 mM Tris pH 7.4, 0.1 M NaCl, and 0.01% Tween.
- the ratio of the maleimido-PEG to protein may be varied according to the preferred level of PEGylation of the protein desired.
- the protein and (Maleimido) 2 -PEG are incubated for one hour at room temperature, although this reaction may be performed at 4°c for longer periods of time. A sample of the reacted mixture may be analyzed by SDS-PAGE to determine the minimal amount of (Maleimido) 2 -PEG reagent needed for complete coupling.
- reaction described above may be used to determine the proper ratio of (Maleimido) 2 -PEG to protein, and then scaled up to produce commercially acceptable amounts of PEGylated dimeric or multimeric proteins.
- PN-l ⁇ and PN-1/8 contain N-glycosylation sites at amino acid residue positions 99 and 140. Therefore, these sites were selected for site-directed mutagenesis to replace the asparagine at one or both of these positions with cysteine.
- PN-l Three sites in PN-l were selected for replacement with cysteine on the basis of the presence of glycosylated residues at a corresponding site in a protein homologous to PN-l.
- Amino acid residue D192 was selected for replacement with cysteine since the proteins angiotensin and Rab ORF1, each which are homologous to PN-l, are N-glycosylated at the amino acids corresponding to this residue in PN-l.
- Amino acid residue E230 was selected for replacement with cysteine since baboon ⁇ ,- antitrypsin ( ⁇ j -AT) , which is homologous to PN-l, is glycosylated at the amino acid residue corresponding to this position in PN-l.
- Amino acid residue H252 was selected for replacement with cysteine since ⁇ 2 - antiplasmin ( ⁇ 2 -AP) , another protein homologous to PN-l, is glycosylated at the corresponding residue.
- amino acid residues were selected for replacement with cysteine on the basis of the position of the amino acid within the three-dimensional structure of PN-l as determined by X-ray crystallography ( Figure 3) .
- the approximate position of the amino acid residues selected for cysteine substitution are indicated by their corresponding amino acid residue number.
- the particular amino acid residues identified for mutagenesis in the present example were selected on the basis of the apparent solvent-accessibility of the amino acid and the apparently few number of interactions with other amino acids in the protein.
- oligonucleotides used to generate specific mutations within the PN-l coding region are as follows:
- the mutants are named according to the single-letter code for the amino acid residue in the native protein, the number of the position of that amino acid within the amino acid sequence of PN-l, and the single-letter code for the amino acid residue substituted at that site.
- the mutant SIC produces a PN-l protein which has the serine at position 1 replaced by cysteine.
- the top sequence for each mutant above indicates the wild type PN-l sequence, while the sequence below indicates the mutation introduced in the coding sequence of the mutant.
- the nucleotides in bold are changed relative to wild type.
- the codon which is double-underlined is the newly- introduced codon for cysteine.
- the underlined sequences in the mutated DNA sequence indicate a restriction enzyme site which is introduced into or removed from the nucleotide sequence of the mutant. Introduction or removal of these restriction sites do not alter the amino acid sequence encoded at that site, but provide a means for screening clones containing DNA subjected to site- directed mutagenesis for incorporation of the oligonucleotide sequence into the PN-l coding sequence. Introduction of the desired mutation was confirmed by restriction enzyme analysis.
- Mutant PN-l proteins containing multiple cysteine- substituted residues were generated by introduction of a first mutation by site-directed mutagenesis as described. After confirmation of the insertion of the first mutation by restriction enzyme analysis, the DNA was subjected to a second round of site-directed mutagenesis using a different oligonucleotide.
- the double mutant N99C;N140C was generated by site-directed mutagenesis with the N99C oligonucleotide and confirmation of the presence of the newly introduced Hpal site in the coding sequence.
- the N99C mutant DNA was then subjected to a second round of site-directed mutagenesis with the N140C oligonucleotide.
- Table G.5A lists the single, double, and triple mutants generated using these techniques and the oligonucleotides described above.
- DNA encoding the mutant PN-l proteins were expressed and the expressed proteins purified as described in section D.3.
- each protein was reacted with the Maleimido-PEG reagent described in F.l according to the general protocol of F.2.
- the mutant N99C;N140C was cysteine-PEGylated using the following protocol.
- Purified N99C;N140C protein was diluted to a concentration of about 200 ⁇ g/ml in 20 mM PIPES pH 6.75, 0.6 M NaCl, 1% glycerol. Approximately 40 ⁇ l of the diluted protein (0.25 nmol) was used for the PEGylation reaction.
- the Maleimido-PEG reagent described in section F.l was diluted in a series of 2-fold dilutions using 10 ⁇ l transfers starting from approximately 2 ⁇ l Maleimido-PEG in a 10 ⁇ l volume of buffer composed of 20 mM Tris pH 7.4, 0.1 M NaCl, and 0.01% Tween. This reaction contained a two-fold excess of the Maleimido-PEG reagent over that required for PEGylation of the number of cysteine sites in the PN-l.
- N99C;N140C protein and maleimido-PEG mixtures were incubated for one hour at room temperature.
- a sample of each of the reacted mixtures was analyzed by SDS-PAGE. Analysis of this gel revealed that the band migrating at the relative molecular weight of unmodified N99C;N140C PN-l disappeared as the ratio of Maleimido-PEG to protein increased. Accordingly, as the amount of unmodified N99C;N140C PN-l in the sample disappeared with increasing Maleimido-PEG concentrations, distinct bands migrating at molecular weights of increasing intervals of approximately 5,000 MW appeared.
- reaction of the PN-l variant produced distinct cysteine-PEGylated proteins containing increasing numbers of PEG units per protein molecule, up to 2 PEG per PN-l molecule, the maximum number of cysteines available in the N99C;N140C PN-l variant.
- Distinct bands representing proteins increasing in relative molecular weight by 5,000 MW intervals is evidence of the specificity of the Maleimido-PEG reaction for attachment of PEG to cysteine residues. If the reaction had resulted in PEGylation of residues other than cysteine, a smear of proteins would appear on the gel, indicating the presence of proteins containing an infinite number of PEG moieties.
- the N99C;N140C PN-l variant was PEGylated using a method similar to that described by Zalipsky in USPN 5,122,614, with the substitution of a paranitrophenol carbonate of PEG for the N-succinimide carbonate of PEG used by Zalipsky as the activated carbonate.
- the protocol used was otherwise identical. Ratios ranging from 1:1 to 100:1 of activated PEG to PN-l mutant (N99C;N140C) were used in the reactions.
- PN-l mutants and cysteine-PEGylated mutants generated are shown in Table G.5A.
- Each of the PN-l site-directed mutant proteins, as well as wild type PN-l, were modified by cysteine-PEGylation using the protocol described in F.2.
- the activity of wild type PN- 1, each of the PN-l site-directed mutants, and the cysteine-PEGylated wild type and mutant proteins was determined using the assay described in D.4.
- PN-l The mutations described here for PN-l can be introduced into any serpin with the expectation of substantially similar effects due to the homology between the members of the serpin protein family.
- the circulating half-life of any protein can be measured by standard methods well known in the art. For example, radioactive PEG-modified protein is injected into a mouse, rat, or rabbit. At various times, blood is withdrawn and the amount of protein remaining in circulation is determined by scintillation counting. Alternatively, PEG-modified PN-l is injected into a mouse, rat, or rabbit. At various times, blood is withdrawn and urokinase inhibitory activity is measured. In some cases, the amount of protein remaining in circulation can be measured with antibody reaction as in an ELIZA or sandwich ELIZA.
- Cysteine-PEGylated PN-l and/or the cysteine- PEGylated PN-l mutants described above may be used in the treatment of a variety of disease states for which PN-l is indicated as therapeutically useful.
- the proteins may be incorporated into a bandage for dressing a wound as described in USPN 5,196,196, herein incorporated by reference with respect to the use (e.g. dosages and routes of administration) of PN-l in wound dressings.
- cysteine-PEGylated PN-l and/or cysteine-PEGylated PN-l mutants may be incorporated as the active ingredient(s) in a pharmaceutical compositions for treatment of inflammation and arthritis, as described in USPN 5,206,017 and USPN 5,326,562, each incorporated herein by reference with respect to the use (e.g. dosages and routes of administration) of PN-l in treatment of such conditions.
- EPO erythropoietin
- the first 27 amino acids of the protein are the EPO signal sequence.
- the amino acid residues which are in bold and underlined above are sites of N-glycosylation in the native EPO protein. These sites are thus selected for replacement with a cysteine residue, which is subsequently modified by PEGylation.
- N24C GCC AAG GAG GCC GAG TGT ATC ACG ACG
- GGC N38C TGC AGC TTG AAT GAG TGT ATC ACT GTC CCA
- N83C GCC CTG TTG GTC TGC TCT TCC CAG CCG
- residues in bold and underlined indicate the nucleotides which are different relative to the wild type EPO DNA sequence and represent the cysteine codon to be introduced into the EPO amino acid sequence.
- mutant EPO proteins which contain a cysteine residue at N24, N38, N83, or a combination of these site (e.g. double and triple mutants) are generated as described, expressed, and purified using techniques well known in the art.
- hGH human growth hormone
- Amino acid residues for replacement with cysteine are selected based upon the solvent- accessibility of the amino acid residue, the proximity of the residue to other amino acid residues with which it may interact, and the distance of the residue from regions of hGH which are known to be important for receptor binding (Cunningham and Wells 1989 Science 244:1081-1085) .
- Oligonucleotides for site-directed mutagenesis are designed so as to introduce a cysteine residue in place of the amino acid residue(s) selected above. Site- directed mutagenesis is performed as described in D.2. The resulting hGH DNA is then inserted into an expression vector, and the resultant protein is expressed in E. coli or other suitable host. The resulting hGH mutant protein is then purified according to methods known in the art.
- the hGH mutant protein is then subjected to cysteine-PEGylation using the method outlined in F.2.
- a sample of a reacted mixture of Maleimido-PEG and hGH mutant protein is analyzed by SDS-PAGE to determine the optimal conditions for cysteine-PEGylation (e.g. the minimal amount of the Maleimido-PEG reagent necessary to provide the desired PEGylated hGH mutant protein) .
- the cysteine-PEgylated hGH protein is then tested for activity by assaying for the ability of the modified protein to bind to purified, truncated hGH receptor, as described in Cunningham and Wells (ibid.).
- Hemoglobin is a tetrameric protein complex composed of two "a” chains and two "b” chains.
- the amino acid sequences of the "a” and “b” chains of hemoglobin, as well as the tetrameric complex of hemoglobin composed of 2 "a” and 2 "b” chains are well known.
- Appropriate amino acid residues which are solvent-accessible and minimally contacted with other side chains are selected for site-directed mutagenesis to cysteine.
- the "a” and “b” chain mutants are then expressed, purified, and allowed to form a tetramer.
- the mutant tetrameric complex is then reacted with various levels of (Maleimido) 2 -PEG as described in F.4 above.
- This reaction can be carried out with very dilute hemoglobin levels to form intramolecular cross-links to stabilize the tetrameric form of hemoglobin, with a minimum number of intermolecular cross-links.
- the reaction can be carried out a higher with a higher hemoglobin concentration, resulting in higher levels of intermolecular cross-linking to stabilize an aggregate of hemoglobin molecules.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14475893A | 1993-10-29 | 1993-10-29 | |
US144758 | 1993-10-29 | ||
PCT/US1994/011624 WO1995011987A1 (fr) | 1993-10-29 | 1994-10-28 | Proteines chimeres contenant des variantes de la protease nexine-1 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0730660A1 true EP0730660A1 (fr) | 1996-09-11 |
EP0730660A4 EP0730660A4 (fr) | 1998-02-25 |
Family
ID=22510003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94931834A Withdrawn EP0730660A4 (fr) | 1993-10-29 | 1994-10-28 | Proteines chimeres contenant des variantes de la protease nexine-1 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0730660A4 (fr) |
JP (1) | JPH09504174A (fr) |
AU (1) | AU685187B2 (fr) |
WO (1) | WO1995011987A1 (fr) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5767078A (en) * | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
GB2318732A (en) | 1996-11-01 | 1998-05-06 | Johnson & Johnson Medical | Wound healing compositions containing alpha-1-antitrypsin |
AU746819B2 (en) | 1997-02-21 | 2002-05-02 | Genentech Inc. | Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies |
US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
EP0981606A2 (fr) * | 1997-05-12 | 2000-03-01 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Procede et construction pouvant inhiber une migration cellulaire |
WO1999003887A1 (fr) * | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derives d'hormone de croissance et proteines associees |
US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
US7153943B2 (en) | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
US7270809B2 (en) | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
US6468532B1 (en) | 1998-01-22 | 2002-10-22 | Genentech, Inc. | Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
US6458355B1 (en) | 1998-01-22 | 2002-10-01 | Genentech, Inc. | Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates |
US7005504B2 (en) | 1998-01-22 | 2006-02-28 | Genentech, Inc. | Antibody fragment-peg conjugates |
CA2338665C (fr) | 1998-08-06 | 2011-01-18 | Mountain View Pharmaceuticals, Inc. | Conjugues peg - urate oxydase et utilisation associee |
US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
IL144259A0 (en) * | 1999-01-14 | 2002-05-23 | Bolder Biotechnology Inc | Methods for making proteins containing free cysteine residues |
US6703480B1 (en) | 1999-11-24 | 2004-03-09 | Palani Balu | Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use |
MXPA02005626A (es) | 1999-12-06 | 2004-09-10 | Pital Sainte Justine H | Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente. |
AU2001238595A1 (en) | 2000-02-22 | 2001-09-03 | Shearwater Corporation | N-maleimidyl polymer derivatives |
US20020042388A1 (en) | 2001-05-01 | 2002-04-11 | Cooper Mark J. | Lyophilizable and enhanced compacted nucleic acids |
JP2004524020A (ja) * | 2001-01-11 | 2004-08-12 | マキシゲン・エイピーエス | 改良された成長ホルモン分子 |
EP1501866A4 (fr) * | 2001-10-02 | 2006-02-08 | Genentech Inc | Variants de ligands apo-2 et leurs utilisations |
US6908963B2 (en) * | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
AU2003210052A1 (en) * | 2002-03-20 | 2003-09-29 | Biopolymed Inc. | Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue |
EP1556076A4 (fr) * | 2002-06-24 | 2009-07-08 | Genentech Inc | Variants du ligand apo-2/trail et utilisations de ceux-ci |
US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
JP4490290B2 (ja) | 2002-12-31 | 2010-06-23 | ネクター セラピューティクス アラバマ,コーポレイション | 加水分解安定性マレイミド末端ポリマー |
WO2005056636A2 (fr) | 2003-12-03 | 2005-06-23 | Nektar Therapeutics Al, Corporation | Procede de preparation de polymeres fonctionnalises par maleimide |
HUE033776T2 (en) | 2004-11-12 | 2018-01-29 | Bayer Healthcare Llc | FVIII site-specific modification |
SG2014009484A (en) | 2005-04-11 | 2014-05-29 | Savient Pharmaceuticals Inc | A variant form of urate oxidase and use thereof |
US8148123B2 (en) | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
ES2538357T3 (es) | 2005-04-11 | 2015-06-19 | Crealta Pharmaceuticals Llc | Formas variantes de urato oxidasa y uso de las mismas |
US8329866B2 (en) | 2005-10-03 | 2012-12-11 | Bolder Biotechnology, Inc. | Long acting VEGF inhibitors and methods of use |
ES2532804T3 (es) | 2006-04-12 | 2015-03-31 | Crealta Pharmaceuticals Llc | Purificación de proteínas con tensioactivo catiónico |
US9377454B2 (en) | 2009-06-25 | 2016-06-28 | Crealta Pharmaceuticals Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
CN114920819A (zh) * | 2022-06-16 | 2022-08-19 | 修正生物医药(杭州)研究院有限公司 | 重组人生长激素突变体、其聚乙二醇衍生物、聚乙二醇衍生物的制备方法及其药物用途 |
CN117567597B (zh) * | 2024-01-17 | 2024-03-22 | 成都艾科斯伦医疗科技有限公司 | 一种抗凝血酶Ⅲ及抗Xa活性检测试剂盒 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0283932A2 (fr) * | 1987-03-20 | 1988-09-28 | Hoechst Aktiengesellschaft | Serpin hybride et l'ADN l'encodant |
WO1991019787A1 (fr) * | 1990-06-21 | 1991-12-26 | Invitron Corporation | Variantes de la protease nexine-i |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
-
1994
- 1994-10-28 WO PCT/US1994/011624 patent/WO1995011987A1/fr not_active Application Discontinuation
- 1994-10-28 JP JP7512667A patent/JPH09504174A/ja not_active Ceased
- 1994-10-28 EP EP94931834A patent/EP0730660A4/fr not_active Withdrawn
- 1994-10-28 AU AU80769/94A patent/AU685187B2/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0283932A2 (fr) * | 1987-03-20 | 1988-09-28 | Hoechst Aktiengesellschaft | Serpin hybride et l'ADN l'encodant |
WO1991019787A1 (fr) * | 1990-06-21 | 1991-12-26 | Invitron Corporation | Variantes de la protease nexine-i |
Non-Patent Citations (2)
Title |
---|
PROTEIN ENGINEERING, vol. 1, no. 1, 1986, pages 29-35, XP002038981 S. JALLAT ET AL: "Altered specificities of genetically engineered alpha-1 antitrypsin variants" * |
See also references of WO9511987A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP0730660A4 (fr) | 1998-02-25 |
JPH09504174A (ja) | 1997-04-28 |
AU685187B2 (en) | 1998-01-15 |
AU8076994A (en) | 1995-05-22 |
WO1995011987A1 (fr) | 1995-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU685187B2 (en) | Chimeric proteins including protease nexin-1 variants | |
US5766897A (en) | Cysteine-pegylated proteins | |
US5312736A (en) | Anticoagulant analogues of the tissue factor extrinsic pathway inhibitor (EPI) with reduced affinity for heparin | |
US5580560A (en) | Modified factor VII/VIIa | |
EP2292650A1 (fr) | Procédés et compositions pour la prévention et le traitement de l'anémie | |
US5187089A (en) | Protease nexin-i variants which inhibit elastase | |
EP0775711A1 (fr) | Peptide a action inhibant l'agregation plaquettaire et procede de production de ce compose | |
WO1995017885A1 (fr) | Inhibiteurs de l'urokinase activateur du plasminogene | |
KR20030060915A (ko) | 단백질 씨 또는 활성 단백질 씨-유사 분자 | |
EP0297913B1 (fr) | Production de kallikréine | |
EP0506821B1 (fr) | Proteine c hybride | |
EP0502872B1 (fr) | Procedes et matieres d'expression de variante de plasminogene humain | |
AU781618C (en) | FVIIa antagonists | |
CA2186908A1 (fr) | Analogues de la .alpha.-1-antichymotrypsine ayant une activite inhibitrice vis-a-vis de l'elastase | |
Morishita et al. | Novel factor Xa and plasma kallikrein inhibitory-activities of the second Kunitz-type inhibitory domain of urinary trypsin inhibitor | |
AU611932B2 (en) | Novel complex | |
US5876971A (en) | Thrombin inhibitor from the saliva of protostomia | |
US8017750B2 (en) | Haemocoagulase | |
EP0387380A1 (fr) | Mutants de l'activateur du plasminogène dérivé de l'urine, leur production et leur utilisation | |
US20150337284A1 (en) | Factor ix variants | |
US8088372B2 (en) | Thrombin mutant | |
CN100392079C (zh) | 蛋白c或活化的蛋白c-样分子 | |
WO1994020537A1 (fr) | Analogues de tfpi non glycosylates | |
AU619803B2 (en) | Rearranged tissue plasminogen activators and method for producing same | |
WO9118987 | Patent bibliography |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19960509 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE FR GB IT LI NL |
|
RHK1 | Main classification (correction) |
Ipc: C12N 15/15 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19980112 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): BE CH DE FR GB IT LI NL |
|
17Q | First examination report despatched |
Effective date: 20000906 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20020621 |